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ABSTRACT 
Synthesis and Biological Activity of Aminoglycosides  
and 1,4-Naphthoquinone Derivatives 
by 
Marina Fosso Yatchang, Doctor of Philosophy 
Utah State University, 2012 
Major Professor: Dr. Cheng-Wei Tom Chang 
Department: Chemistry and Biochemistry 
Aminoglycosides, such as streptomycin, kanamycin and neomycin, are a group of 
naturally occurring antibiotics that structurally consist of various amino-modified sugars. 
They have long been used clinically for their broad-spectrum activity against Gram-
negative and Gram-positive bacteria. However, the incidence of bacterial resistance has 
considerably hampered their clinical efficacy, forcing researchers to explore new 
applications of aminoglycosides. 
An aminoglycoside belonging to the class of pyrankancin was identified as the 
lead compound in the treatment of spinal muscular atrophy, an infantile disease caused by 
nonsense mutations. To further investigate its therapeutic capabilities, additional batches 
of this lead compound were prepared and its mode of action study revealed an 
unprecedented SMNΔ7 read-through event.
iv 
 
In addition, the chemical derivation of kanamycin B was examined in the aim of 
developing potential agro fungicides. Indeed, a library of kanamycin B analogs was 
synthesized to investigate the length of the alkyl chain and its position in kanamycin B 
that will confer to this latter an optimum antifungal activity. Results of this study 
revealed that the attachment of an octyl group at the O-4´´ position of the core structure 
of the classical aminoglycoside kanamycin B converts this obsolete drug into a broad-
spectrum fungicide. Another interesting finding was the simultaneous loss of antibacterial 
activity usually observed in aminoglycosides. This was essential as it paves the way for 
the development of a new class of aminoglycoside-based fungicides suitable for use in 
crop disease application. 
Molecules with naphthoquinone scaffolds are also of great interest due to their 
important biological and pharmaceutical applications. Three synthetic protocols were 
examined to optimize the production of the 1,4-naphthoquinone derivatives and to 
conveniently synthesize a library of novel cationic anthraquinone analogs. The 
antibacterial activities of these compounds were evaluated and they were found to display 
much higher levels of activities against Gram-positive than Gram-negative bacteria. In 
addition, with double alkyl chains of various lengths (C2 –C12) at N-1 and N-3 positions, 
a synergistic effect of the alkyl groups was observed, suggesting the importance of 
overall lipophilicity in the activity of this class of compounds against Gram-positive 
bacteria. 
(287 pages)
v 
 
PUBLIC ABSTRACT 
Synthesis and Biological Activity of Aminoglycosides  
and 1,4-Naphthoquinone Derivatives 
by 
Marina Fosso Yatchang, Doctor of Philosophy 
Utah State University, 2012 
The research described in this dissertation is at the interface of organic chemistry 
and biology, and it aimed at designing and synthesizing biologically active molecules for 
the possible development of therapeutic agents. 
Spinal muscular atrophy is an incurable disease that affects 1 in every 6000 
babies, making it the leading genetic cause of infant mortality. While no treatment is 
available, efforts are being taken to solve this issue. Part of the work outlined in this 
dissertation was carried out in collaboration with researchers from the University of 
Missouri to investigate a potential therapeutic for this disease. 
In addition, the continuous outbreak of diseases caused by bacteria demands for 
new and improved antibiotics that could help eradicate those pathogens. My research thus 
allowed me to discover molecules with interesting activity against bacteria for the 
possible development of potential antibacterial agents. 
Finally, my research also allowed me to develop potential agro fungicides, which 
are still very much needed nowadays. Many crop diseases are due to fungal infections,
vi 
 
 which globally cause enormous economic losses. The use of fungicides is still the main 
strategy to control these diseases. However, current agro fungicides show some 
limitations. This is illustrated with Fusarium head blight (FHB), a destructive and costly 
disease of wheat, barley and other small grains, whose economic losses in the Central 
United States alone were estimated to $2.7 billion.
vii 
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CHAPTER I 
GENERAL INTRODUCTION 
Between 1940 and 2004, a staggering 335 infectious diseases have been 
discovered.
1
 And with an estimated three new diseases being identified every couple of 
years, this number is constantly increasing.
2 
Furthermore, diseases that were once 
treatable are resurging as a threat for a significant portion of the population. Through 
mutation or genetic exchange, infectious agents are able to develop resistance against 
available drugs and evolve into new deadly strains.  
This alarming prevalence of drug-resistant microorganisms, together with the 
continuous emergence of infectious diseases, has enabled these pathogens to be two steps 
ahead of humans and contributed to ranking infectious diseases among the leading causes 
of mortality in the world.
3 
 
In addition to these emerging infectious diseases, which are caused by external 
factors (bacteria, viruses, and fungi), abnormalities in an individual’s genome could also 
result in disorders called genetic diseases. Genetic diseases can either be inherited from 
the parents, or they could result from developed mutations or changes on the DNA. 
Changes that occur on a single gene give rise to Mendelian or single-gene disorders; 
meanwhile, multifactorial genetic diseases are caused by mutations in several genes, 
often coupled with environmental factors.  
Spinal muscular atrophy (SMA) is an example of Mendelian disorders. It is 
caused by the homozygous loss of the Survival Motor Neuron 1 (SMN1) gene.
4 
It is an 
incurable neuromuscular disease characterized by the death of motor neurons present in
2 
 
the anterior horn of the spinal cord.
5,6
 It manifests itself by the progressive weakness and 
degeneration of the muscles.
7
 Four types of SMA exist and they are categorized based 
upon the disease severity and the age of onset:
8 
 Type I or Werdnig-Hoffman disease is the most severe form of SMA and 
manifests itself in the first months of life (0-6 months), 
 Type II or Dubowitz disease is the intermediate form with an age of onset 
between 6 and 18 months, 
 Type III or Kugelberg-Welander disease manifests after 18 months 
(juvenile form), 
 Type IV or adult-onset form appears after 35 years.  
With an incidence of one in every 5,000 – 10,000 births, SMA is the leading 
genetic cause of infant mortality.
9,10
  
In light of these observations, the need to develop new and improved drugs that 
will help treat these diseases and alleviate this global threat becomes obvious. And what 
better place than nature to find the inspiration! This is clearly evidenced by the number of 
approved and clinical-trial drugs derived from natural products.
11,12
 For example, 26% of 
the new drugs approved by the Food and Drug Administration (FDA) in 2009-2010 were 
derived from nature.
13 
   
Aminoglycosides and naphthoquinones are two abundant, naturally occurring 
classes of compounds that have significant pharmacological properties. Anthracyclines, 
which can be viewed as 1,4-naphthoquinone derivatives, and aminoglycosides have even 
3 
 
been  categorized as “drug-productive scaffolds”.13 It thus becomes apparent why we 
have directed our efforts toward these two classes of compounds.  
 
I.1. Aminoglycosides 
I.1.1. Classification and traditional mode of action of aminoglycosides 
Streptomycin (Figure 1) was the first aminoglycoside to be discovered. Isolated 
from the actinobacterium Streptomyces griseus in 1944,
14
 it was the first antibiotic 
effective in the treatment of tuberculosis. Since then, the broad-spectrum of activity of 
aminoglycosides against both Gram-negative and Gram-positive bacteria has stimulated 
multitude interests. 
Aminoglycosides are a group of naturally occurring antibiotics that structurally 
consist of various amino-modified sugars. 2-Deoxystreptamine (2-DOS) has been found 
to play a pivotal role in the biological activity of aminoglycosides,
15,16
 resulting in its 
derivatives being among the most studied aminoglycosides. This includes the two major 
classes of neomycin and kanamycin (Figure 2). Members of the neomycin class can be 
viewed as 4,5-disubstituted 2-deoxystreptamines, while the kanamycin class encompasses 
the 4,6-disubstituted 2-deoxystreptamines. 
 
 
 
Figure 1: Structure of streptomycin. 
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Figure 2: Structures of 2-deoxystreptamine (2-DOS) aminoglycosides 
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Aminoglycosides are well known for their traditional role of antibacterial agents. 
Their mode of action has been extensively studied. They have been found to exert their 
bactericidal action by selectively binding to the A-site (aminoacyl site) decoding region 
of the 16S ribosomal RNA (rRNA) of bacteria.
17,18 
During the protein synthesis, binding 
of the correct tRNA to the mRNA causes conformational changes of two adenine 
residues (A1492 and A1493) in16S rRNA, allowing them to contact with the mRNA-
tRNA codon-anticodon hybrid.
19
 Since mispairing of codon and anticodon cannot induce 
this conformational change, this “proof-reading” process helps to ensure translational 
fidelity. However, the binding of the aminoglycosides at the decoding region impacts the 
conformational changes of A1492 and A1493.
20,21
 As a result, discrimination between 
cognate and near-cognate tRNA is reduced in the presence of aminoglycosides, enabling 
codon misreading.
22
 Misfolded proteins are then produced, some of which are 
incorporated in the bacterial membrane, leading to the loss of membrane integrity and 
increased permeability for the antibiotics. As a consequence, aminoglycosides 
accumulate rapidly in the cytoplasm and saturate all ribosomes, resulting in cell death 
(Figure 3).
23-25
 
Despite these noticeable advantages, the nephrotoxicity and ototoxicity associated 
with aminoglycosides have considerably hampered their clinical usefulness.
26
  
Aminoglycosides have also suffered from the emergence of drug-resistant 
bacteria. Over fifty aminoglycoside-deactivating enzymes have been identified.
24, 27-30
 
They act by modifying the structures of aminoglycoside antibiotics. This could be 
accomplished either through phosphorylation of a hydroxyl group (aminoglycoside 
6 
 
phosphoryltransferases, APH), adenylation of a hydroxyl group (aminoglycoside 
adenylyltransferases, AAD or ANT), or acetylation of an amino group (aminoglycoside 
acetyltransferases, AAC). Other mechanisms of resistance include the decrease of drug 
uptake into bacteria and the alteration of the ribosomal binding sites.  
All these phenomena have rendered these once-before-acclaimed drugs obsolete, 
resulting in a growing interest in the development of new and modified aminoglycosides, 
with improved antibacterial activity.
24,31
 Despite all the efforts invested, a huge gap is 
still to be filled. This has thus forced other research groups to explore new applications of 
aminoglycosides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Bactericidal action of aminoglycosides
 
(Adapted from Kohanski, 2010 [Ref. 25]) 
I.1.2. Aminoglycosides in the treatment of genetic diseases 
The selective binding of aminoglycoside antibiotics toward bacterial ribosome is 
crucial for their therapeutic use, and this is largely achieved through critical interactions 
Cell death 
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of the drug with nucleotides of the rRNA that are not similar in bacteria and human.
32
 For 
example, studies have demonstrated that A1408 and G1491 of the bacterial decoding site 
determine the selectivity of aminoglycosides.
33,34
 Eukaryotic cytoplasmic ribosomes are 
insensitive to aminoglycosides because a guanine residue is found at position 1408 and 
an adenine residue at position 1491 of 16S rRNA, which are all not able to interact with 
aminoglycosides.  
However, it was found that certain aminoglycosides can bind to the small subunit 
of bacterial and eukaryotic ribosomes, especially at sites where nucleotides that are 
conserved between bacteria and eukaryotes are involved.
35
 For example, apramycin and 
geneticin (Figure 4) are known to bind to the human decoding site.
32,36
 This disadvantage 
turned out to be useful in the treatment of genetic diseases caused by nonsense mutations.  
 
 
 
Figure 4: Structures of apramycin and geneticin (G418) 
More than 1800 distinct heritable human diseases are caused by nonsense 
mutations,
37
 during which a change in a single nucleotide in a DNA sequence converts a 
codon that specified an amino acid into a stop codon. As a result, protein translation 
prematurely terminates, leading to the production of non-functional shortened 
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proteins.
38,39
 In 1985, Burke and Mogg
40
 showed that aminoglycosides can suppress the 
effect of a nonsense mutation; by binding to the decoding site, aminoglycosides reduce 
the translation fidelity and allow a random amino acid to be incorporated at a premature-
termination codon in mammalian cells. As a result, the protein translation can proceed 
through the natural stop codon (Figure 5).
41 
 
A)  Normal protein translation 
 
 
 
 
 
 
 
 
 
B) Nonsense mutation (C→A) - Premature termination of protein translation 
 
 
 
 
 
 
 
 
 
C) Aminoglycoside insertion of a near-cognate tRNA - Restored protein translation 
 
 
 
 
 
 
 
 
 
 
Figure 5: Suppression of nonsense mutation by aminoglycosides 
(Adapted from Malik, 2010 [Ref. 41])
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This concept has introduced novel research avenues in the field of 
aminoglycosides, allowing them to emerge as stop codon read-through inducers. This 
new ability was tested as a therapeutic approach for human genetic diseases, including 
spinal muscular atrophy. 
 
I.1.3. Aminoglycosides as antifungal agents 
Fungal infections are mainly responsible for the huge economic losses generated 
from crop and turf diseases. Current strategies to control these infections include the 
direct application of chemical fungicides.
42 
However, their associated toxic side effects 
toward animals and humans oblige the growers to reduce their dependency on these 
antibiotics and seek for better alternatives. Unfortunately, while enormous efforts have 
been devoted to the development of new antibacterial, antiviral, and anticancer 
therapeutics, only a few new fungicides have been introduced since the mid-1980s.
43 
Fungi are eukaryotic organisms whose cells contain a nucleus enclosed within a 
distinct membrane. As in any eukaryote, anionic sphingolipids are found on the outer 
surface of fungal cell membranes. Therefore, cationic molecules such as aminoglycosides 
would be expected to interact with the fungal cell walls. As a matter of fact, it was 
recently reported that certain commercially aminoglycosides are inhibitory to plant 
pathogenic oomycetes.
44 
However, the major drawback related to the use of 
aminoglycosides to combat crop diseases is their potential contribution to the propagation 
of bacterial resistant strains.
45,46
 Therefore, the best aminoglycoside agrofungicide 
candidates will be those that completely lose their antibacterial capabilities while gaining 
some antifungal activities. 
10 
 
I.2. 1,4-Naphthoquinone derivatives 
I.2.1. History and biological functions 
1,4-naphthoquinone belongs to the broad class of compounds called quinones. 
1,4-naphthoquinone derivatives are of particular interest because of their large occurrence 
as natural products.
47-51
 They are found in various parts of plants such as leaves, flowers, 
roots, bark, and wood. In addition, they exhibit a wide range of interesting biological 
activities.
52-56 
Molecules bearing naphthoquinone scaffold have also been employed as 
inhibitors against vitamin K dependent carboxylase,
57
 protein kinase,
58
 coenzyme Q,
59
 
and as growth stimulator for bifidobacteria.
60
  
A representative class of 1,4-naphthoquinone derivatives is the group of fat-
soluble compounds called vitamin K. This includes the naturally occurring vitamin K1, or 
phylloquinone, required for blood coagulation, and vitamin K2, or menaquinone, which is 
of vital importance for bone health (Figure 6). A synthetic form of vitamin K is vitamin 
K3 or menadione (Figure 6), which is often used as a quinone model for in vivo studies.  
Menadione has been shown to undergo both redox cycling and arylation reactions. 
This is mainly due to the two carbonyl groups, which give the ability to 1,4-
naphthoquinone derivatives to accept one and/or two electrons.
61 
1,4-naphthoquinone 
derivatives can accept an electron to form the semiquinone radicals upon catalysis by 
flavoenzymes such as NADPH-cytochrome P-450 reductase (Figure 7).
52,62,63 
The 
semiquinone radicals can be further reduced to hydroquinones. In aerobic conditions, 
reactive oxygen species (ROS) are produced by transfer of electrons to oxygen. ROS is 
11 
 
commonly used to refer to superoxide, hydroxyl radical, and hydrogen peroxide, which 
are all known to break DNA strands.
64-66
 
 
 
 
 
Figure 6: Structures of vitamin K1 (phylloquinone), vitamin K2 (menaquinone), and 
vitamin K3 (menadione) 
 
 
  
 
Figure 7: 1,4-Napthoquinone derivatives as redox cyclers 
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In addition, 1,4-naphthoquinone derivatives can undergo arylation reactions. They 
contain electrophilic α,β-unsaturated carbonyl groups, which can react with nucleophilic 
moieties of proteins, such as thiolate groups, and form covalent bonds. This usually 
results in the inactivation and loss of protein function.
67
 
 
I.2.2. 1,4-Naphthoquinone derivatives as antibacterial agents 
Various 1,4-naphthoquinone derivatives with antibacterial activity are known 
(Figure 8). This includes plumagin, juglone and lawsone, which are naturally occurring 
naphthoquinones of plant origin.
68 
Alkannin, shikonin, and their derivatives are other 
natural naphthoquinone products whose antimicrobial activity has been widely 
investigated.
69
 Pleosporone was isolated from a pleosporalean ascomycete.
70 
 
 
 
Figure 8: Structures of antibacterial 1,4-naphthoquinone derivatives 
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1,4-naphthoquinone derivatives can exert their antibacterial activity by 
decoupling of oxidative phosphorylation, a process essential for ATP synthesis. Because 
of their ability to accept electrons, they can compete with electron carriers such as 
coenzyme Q and uncouple the electron transport chain.
71
  
In addition, 1,4-naphthoquinone derivatives are known to inhibit the growth of  
Gram-positive bacteria such as Staphylococcus aureus, Enterococcus faecium, and 
Bacillus subtillus. However, they are ineffective against Gram-negative bacteria such as 
Escherichia coli and Salmonella typhimurium.
69
 
 
I.3. Research summary 
The aim of this research was to synthesize biologically active molecules. First of 
all, new therapeutic potentials of antibiotic aminoglycosides were investigated. A 
pyranmycin compound, an aminoglycoside, was re-synthesized and its mode of action in 
the treatment of spinal muscular atrophy was studied (chapter II). In addition, synthesis 
of various kanamycin B analogs revealed that a simple alkylation can convert this well-
known antibacterial into an antifungal agent with potential use in agriculture (chapter III). 
Finally, a library of cationic 1,4-naphthoquinone derivatives was developed and their 
antibacterial activity studied (chapter IV). 
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CHAPTER II 
AMINOGLYCOSIDES AS THERAPEUTICS 
FOR SPINAL MUSCULAR ATROPHY
a
 
II.1. Rationale 
 Spinal muscular atrophy (SMA) is an autosomal recessive disease. SMA patients 
carry a pair of defective chromosomes 5 that both lack the Survival Motor Neuron-1 
(SMN1) gene on the long (q) arm, at position 13.2.
72
 SMN1 produces full-length 
transcripts that translate into high levels of the survival motor neuron (SMN) protein, 
essential for the maintenance of motor neurons (specialized nerve cells that control 
muscle movement). SMN2, a nearly identical gene to SMN1 also found at locus 5q13.2,
4
 
exhibits a critical C to T nucleotide variation within the 5´ end of exon 7.
73
 This causes 
SMN2-derived transcripts to undergo alternative splicing at the junction of intron 6 and 
exon 7.
74,75
 As a result, 90% of the SMN2-derived transcripts lack the exon 7 and will 
therefore code a truncated and unstable SMN∆7 protein; only 10% will produce a fully 
functional SMN protein.
4,76
 Therefore, in the absence of SMN1, SMN2 alone cannot 
produce enough SMN protein for the maintenance of motor neurons. However, an 
increase in the number of SMN2 copies will result in more SMN2-derived SMN protein, 
and thus reduce the severity of SMA.  
Dr. Christian Lorson and co-workers (Department of Veterinary Pathobiology, 
Bond Life Sciences Center, University of Missouri) have previously reported the ability 
                                                          
a
 Part of this chapter was coauthored by Virginia B Mattis, Marina Y Fosso, Cheng-Wei  
Chang and Christian L Lorson. Reproduced with kind permission from BMC Neurosc. 
2009, 10:142. Copyright © 2009, BioMed Central. 
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of two aminoglycosides, tobramycin and amikacin (Figure 9), to elevate the SMN protein 
levels in SMA cells.
77 
By employing the capacity of aminoglycosides to read-through 
ribosomes past stop codons (see chapter I for more details), tobramycin and amikacin 
enable the incorporation of missing sequences at the C-terminus of SMN∆7 protein, 
thereby restoring the stability and the functionality of this novel SMN protein.  
In light of these results, through collaboration with Dr. Lorson, our libraries of 
previously synthesized aminoglycosides were screened to identify TC007 (Figure 9) as 
the lead in the treatment of spinal muscular atrophy.
78
 Therefore, my goal was to prepare 
more TC007 in order to study its mode of action in the treatment of spinal muscular 
atrophy. 
 
 
Figure 9: Structures of tobramycin, amikacin, and TC007 
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II. 2. Results and discussion 
II.2.1. Synthesis of TC007 
TC007 belongs to the class of pyranmycin compounds. These are neomycin 
analogs and they result from the replacement of the neobiosamine core (rings III and IV) 
of neomycin with a pyranose (Figure 10).
79
 It has been previously demonstrated that the 
glycosidic bond of a furanose is more prone to acid cleavage than that of a pyranose.
80 
Pyranmycin could therefore survive harsh acidic conditions that will otherwise degrade 
neomycin.
81 
Following the protocol previously described by Dr. Ravi Rai,
79 
the synthesis of 
TC007 will start from the commercially available neomycin B. Conversion of the amino 
groups into azido groups followed by benzylation afforded compound 1
82
 (Scheme 1). 
Cleavage of the glycosidic bond between rings II and III was accomplished by refluxing 
1 in the presence of copper (II) chloride, and this gave the known neamine derivative 2.
82
 
The free hydroxyl group at the 5-position is required for the final compound to be a 4,5-
disubstituted 2-deoxystreptamine, thus an analog of neomycin. 
 
               
 
Figure 10: Structures of neomycin and pyranmycin 
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Scheme 1: Synthesis of the neamine derivative acceptor 2 
The synthesis of the glycosyl donor 8 started from the commercially available 
diacetone-D-glucose 3 (Scheme 2). Swern oxidation of 3 and reduction of the 
corresponding ketone with NaBH4 gave the epimer alcohol 4.
83
 Triflation, which converts 
the free hydroxyl group into the better triflate leaving group, and SN2 azido substitution 
afforded compound 5.
84
 Acid-catalyzed hydrolysis, followed by acetylation, provided the 
tetraacetyl pyranose 6.
85
 Treatment with hydrazine acetate selectively hydrolyzed the 
acetyl group at the anomeric position to give 7,
86
 whose free hydroxyl group was then 
activated in the presence of trichloroacetonitrile to afford our glycosyl donor 8.
87
  
With the neamine acceptor 2 and the glycosyl donor 8 on hand, we were ready to 
embark on the synthesis of TC007 (Scheme 3). Glycosylation of 2 and 8 in the presence 
of the Lewis acid BF3-OEt2 provided compound 9.
87
 The acetyl group present at C-2 of 
18 
 
the glycosyl donor 8 controls the formation of the β-glycosidic bond in 9 (Scheme 4). 
Indeed, as the donor 8 gets activated in the presence of BF3-OEt2, an oxocarbenium 
intermediate is formed, which in the presence of a 2-O-acyl group will give an 
acyloxonium intermediate. Therefore, the attack by a nucleophile (acceptor 2) can only 
happen from the open top face, resulting in the formation of the β-anomer in 9. The acetyl 
groups in compound 9 will then be hydrolyzed using K2CO3 in methanol. Staudinger 
reduction of the azide, followed by hydrogenolysis and ion-exchange, provide TC007 as 
a chloride salt. 
 
 
 
Scheme 2: Synthesis of the glycosyl donor 8 
 
19 
 
 
 
Scheme 3: Synthesis of TC007 
 
 
 
 
 
 
Scheme 4: Formation of the β-glycosidic bond in compound 9 
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II.2.2. Mode of action of TC007 in the treatment of spinal muscular atrophy  
SMN proteins localize in nuclear bodies known as gems.
88
 Gem numbers have 
been frequently used as a biomarker for total cellular SMN protein levels in SMA patient 
fibroblasts.
77,89-93  
In a low throughput cell-based screen, TC007 and other 
aminoglycosides were found to elevate SMN and gem numbers in SMA type I 
fibroblasts.
78 
Patient fibroblasts treated for 48 h in 100 µg/mL of aminoglycoside-media 
showed a higher amount of SMN nuclear gems (Figure 11).
78
 TC007 was found to be 
even more effective than valproic acid (VPA), a previously identified histone deacetylase 
inhibitor compound known to increase SMN expression by stimulating the SMN2 
promoter and SMN exon 7 inclusion. 
 
 
  
  
 
Figure 11: Increase in SMN-positive gems (white arrows) 
 after treatment with TC007
78
 
TC007 was found to induce SMN protein levels by a novel SMN∆7 read-through 
event. Experiments carried out in Dr. Lorson’s laboratory revealed that TC007 causes the 
21 
 
ribosome to incorporate a tyrosine into the first stop codon of SMN∆7 exon 8 and read-
through until the second stop, 16 nucleotides downstream (Figure 12).
78
 This allows the 
translational machinery to elongate the truncated protein by additional five amino acids, 
length which has been demonstrated sufficient to restore more functionality to the 
protein. This SMN read-through protein, while in the low level, enters into an SMN 
complex with the existing full-length protein, resulting into a small increase in SMN-
functional (SMN-Fl) protein after treatment.  
Animal model experiments performed in Dr. Lorson’s laboratory have revealed 
that TC007 can actually lessen the severity of SMA.
94
 As a result, subcutaneous 
administration of TC007 was found to increase myofiber size and gross motor function in 
SMA mice (Figure 13).
95
 
 
 
 
 
Figure 12: Schematic of SMN C-termini
78
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Figure 13: Increase in muscle fiber size of TC007-treated mice
95
 
 
II. 3. Conclusion 
 The bioactivity screening of a library of previously synthesized aminoglycosides 
has identified TC007 as the lead compound in the treatment of spinal muscular atrophy. 
To further investigate its mode of action, more TC007 was synthesized from neomycin 
B. The use of copper (II) chloride in the cleavage of the glycosidic bond between rings II 
and III of neomycin B was found to be slightly more effective than the previously used 
MeOH/HCl mixture.  
TC007 was found to act through an unprecedented SMN∆7 read-through event. 
TC007 triggers the insertion of an amino acid such as tyrosine, in the premature stop 
codon and allows the ribosome to read-through until the following natural stop codon. 
This elongates the truncated SMN∆7 protein by an additional five amino acids, enabling 
23 
 
it to regain functionality. These findings could lead to the development of novel 
therapeutic approaches for the treatment of spinal muscular atrophy. 
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CHAPTER III 
STRUCTURAL OPTIMIZATION OF ANTIFUNGAL 
KANAMYCIN B ANALOGS
b
 
III.1. Rationale  
A recent report has demonstrated that aminoglycosides, including neomycin, 
paromomycin, ribostamycin, and streptomycin (Figures 1 and 2), can manifest modest to 
excellent antifungal activity against a panel of pathogenic fungi.
44 
However, all these 
aminoglycosides are clinically used antibiotics for the treatment of human bacterial 
pathogens. Therefore, if any of them happened to be involved in plant disease 
management, microbial resistance could easily be extended to human, leading to an 
increase of human illnesses and possibly death. This phenomenon has previously been 
observed with farm animals, when the overuse of in-feed antibiotics in livestock resulted 
in the detection of a large number of drug-resistant bacteria in human.
96
  
In addition, among the two most commonly used classes of aminoglycosides, 
neomycin and kanamycin, this study limited itself to the neomycin class of 
aminoglycosides (neomycin, paromomycin, and ribostamycin). No representative 
member of the kanamycin class was included.  
To solve both issues, we decided to investigate the antifungal activity of some 
kanamycin class aminoglycosides. In addition, these aminoglycosides needed to be 
inactive against bacteria in order to be the ideal antifungal agent candidates. 
                                                          
b
 Part of this chapter was coauthored by Chang, C.-W. T.; Fosso, M.; Kawasaki, Y.; 
Shrestha, S.; Bensaci, M.; Wang, J.; Evans, C. K.; Takemoto, J. Y. Reproduced with kind 
permission from J. Antibiot. 2010, 63, 667-672. Copyright © 2010, Nature Publishing 
Group. 
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Kanamycin B (Figure 2) is a naturally occurring antibacterial aminoglycoside. As 
the prototypal model of the kanamycin class of aminoglycosides, its antibiotic efficacy 
has been excessively used. The net result was the high prevalence of resistant bacteria 
and thus the loss of its clinical attractiveness. In the effort to restore its antibacterial 
activity, our group has been involved in the development of new strategies to derivatize 
this class of compounds and had previously synthesized a library of kanamycin B 
analogs.
97-99 
Screening of this library of analogs uncovered few compounds that inhibited 
the growth of fungi and yeasts. One compound, FG08, displayed broad spectrum 
fungicidal activity coupled with the loss of antibacterial activity. Therefore, more FG08 
had to be prepared to investigate its mechanism of action. In addition, other kanamycin B 
analogs would be synthesized in the aim of developing potential antifungal agents. 
 
III. 2. Results and discussion 
III.2.1. Investigation of the optimum chain length  
The surprising antifungal activity of FG08 was attributed to the attachment of a 
long (C8) alkyl chain. To investigate the chain length that will confer the optimum 
antifungal activity, two other kanamycin B analogs were synthesized: FG01, with a 
shorter (C4) alkyl chain, and FG02, with a longer (C12) alkyl chain. 
 
a) Retrosynthetic analysis of FG01, FG02 and FG08  
FG01, FG02, and FG08 are all kanamycin B analogs and thus share a pseudo-
disaccharide core (neamine) substituted at the 6-position. Their syntheses could therefore 
start from the neamine derivative 10
97
 and the phenylthioglycosyl donor 11 (Scheme 5). 
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Unlike the β-glycosidic bond, there is no general and stereospecific protocol for the 
formation of the α-glycosidic bond. However, a 2-O-Bn group does not favor the 
formation of the acyloxonium intermediate required for β-selectivity. Therefore, the 
phenylthioglycoside 11 will enable the formation of the α-glycosidic bond between rings 
II and III due to the anomeric effect. Indeed, upon activation by NIS and TMSOTf, 11 is 
converted into an oxocarbenium intermediate (Scheme 6). Nucleophilic attack by the 
acceptor 10 can occur from the top face to give the β-anomer, or from the bottom face to 
give the α-anomer. Because of the orbital overlap, the β-anomer is less favored than the 
α-anomer. Therefore, the α-anomer will be obtained as the major product. In addition, 
since 10 has two free hydroxyl groups, steric hindrance will prevent 5-OH from acting as 
the nucleophile, allowing glycosylation to happen only at the 6-position. 
 
 
 
Scheme 5: Retrosynthetic analysis of FG01, FG02, and FG08 
 
 
b) Syntheses of FG01, FG02 and FG08 
Starting from neamine 12,
100 
conversion of the amino groups to azido groups gave 
13
101
 (Scheme 7).
 
Regioselective protection of the 1,2-diol at positions 5 and 6 gave 14.
97
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Acetylation of the hydroxyl groups at positions 3´ and 4´, and acid cleavage of the 
cyclohexylidene protecting group afforded the neamine derivative 10. 
 
 
 
Scheme 6: Anomeric effect 
 
 
 
 
 
 
Scheme 7: Synthesis of the neamine derivative acceptor 10 
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The synthesis of the glycosyl donors started from the known compound 15
102 
(Scheme 8). Acetonolysis, followed by regioselective protection of the hydroxyl groups 
at positions 4 and 6 afforded 16.
102 
Benzylation and acid cleavage of the benzylidene 
protecting group gave 17,
102
 as a 1,3-diol. Selective tosylation of the primary alcohol and 
reduction with LiAlH4 gave 18.
103
 Alkylation using n-butyl bromide, n-octyl bromide, 
and n-dodecyl bromide gave the glycosyl donors 11a, 11b, and 11c, respectively. 
 
 
 
Scheme 8: Synthesis of the glycosyl donors 11a, 11b, and 11c 
 
 
With the neamine acceptor 10 and the glycosyl donors 11a, 11b, and 11c on hand, 
we were ready to embark on the synthesis of FG01, FG02, and FG08 (Scheme 9). 
Glycosylation in the presence of NIS and TMSOTf followed by acetonolysis using 
NaOMe in MeOH/THF mixture afforded 19. Staudinger reduction of the azide into an 
amine, hydrogenation, and ion-exchange provided FG01, FG02, and FG08 as chloride 
salts. 
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Scheme 9: Synthesis of FG01, FG02, and FG08 
 
 
 
c) The C8 alkyl chain confers optimum antifungal activity 
 
Through collaboration with Dr. Jon Takemoto (Department of Biology, Utah 
State University), the effectiveness of each of the FG compounds was evaluated. The 
synthesized kanamycin B analogs were tested against Rhodotorula piliminae (Figure 
14).
104
 From the disk diffusion growth inhibitory assay, FG08 gave a larger zone of 
inhibition and thus is more active than FG01 and FG02 against R. piliminae.  
Further alkyl chain lengths were not investigated because from a similar study of 
alkyl chain length vs. aminoglycoside bioactivity,
105
 it was reported that compounds with 
C7 and C10 alkyl chains showed reduced activities compared to the parent compound. 
Therefore, we reasoned that the C8 alkyl chain will still be the best at conferring an 
optimal antifungal activity. 
30 
 
 
 
 
Figure 14: Disk diffusion inhibitory assay of FG01, FG02, and FG08 
Based on these results, more emphasis was directed toward the antimicrobial 
activity of FG08. Microbroth dilution assays performed in Dr. Takemoto’s laboratory 
revealed that FG08 exhibits little to no activity against Gram-positive and Gram-negative 
bacteria (Table 1). Its MIC values against both types of bacteria were at least 125-fold 
higher than shown by kanamycin B (Table 1).  
In addition, FG08 was found to inhibit the growth of a wide range of yeasts, 
oomycetes, and true fungi with MICs ranging between 3.9 and 31.3 μg/mL (Table 1).104 
On the other hand, kanamycin B was not active against those same microbes. 
In light of these results, the ability of FG08 to control Fusarium head blight 
(FHB) was evaluated. 
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Table 1: Minimal inhibitory concentrations (MICs) of FG08 and kanamycin B
104 
 MIC (µg/mL) 
Organism FG08 Kanamycin Ba 
Bacteria   
Escherichia coli TG1b 125-250 1.95 
Staphylococcus aureus (ATCC 25923)c 250 <0.98 
Pseudomonas aeruginosa (ATCC 27853)b 250 1.95 
Enterococcus faecalis (ATCC 29212)c 125-250 <0.98 
Klebsiella pneumoniae (ATCC 138883)b 250 1.95 
Klebsiella pneumoniae (ATCC 700603)b 250 1.95 
   
Fungi   
Rhodotorula pilimanae (ATCC 26423) 7.8 >250 
Candida albicans (ATCC 10231) 31.3 >250 
Saccharomyces cerevisias W303 3.9 >250 
Fusarium graminearum B-4-5A 31.3 >250 
Fusarium oxysporum 7.8 >250 
Ulocladium spp. 7.8 NDd                                                                                         
Pythium irregular 15.6 ND 
Pythium ultimum 15.6 ND 
Phytophthora parasitica 15.6 ND 
Rhizopus stolonifer 31.3 ND 
Cladosporium cladosporioides 31.3 ND 
Curvularia brachyspora 31.3 ND 
Bortrytis cinerea 31.3 ND 
Phoma spp. 31.3 ND 
a
Microboth dilution assays were performed at least twice, and each in triplate 
b
Gram-negative bacteria 
c
Gram-positive bacteria 
d
Not determined 
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III.2.2. Antifungal activity of FG08 against Fusarium graminearum 
F. graminearum is the causative agent of Fusarium head blight (FHB) and affects 
wheat, barley, and maize. With economic losses averaging $3 billion annually, FHB is 
among the most serious plant disease the U.S. has encountered.
106
 Efforts to eradicate this 
crop disease have not been successful yet. Therefore, the development of a fungicide that 
will inhibit F. graminearum is much awaited. 
 
a) Green house experiments 
FG08 was investigated for its ability to control FHB of wheat.
104
 Leaf infection 
assays performed by Yukie Kawasaki, a graduate student in Dr. Takemoto’s laboratory, 
revealed the ability of FG08 to suppress in planta F. graminearum infection at its in vitro 
MIC value. When FHB-susceptible wheat leaves were inoculated with 10 µL of a 
mixture of FG08 (30 µg/mL) and suspensions of F. graminearum macronidia, not only 
was mycelial growth prevented (Figure 15, upper panel), but a 5-fold decrease in leaf 
lesions was also observed (Figure 15, middle panel, white bars). At 180 µg/mL, FG08 
was found to be phytotoxic (Figure 15, lower panel).  
In addition, FG08 reduced the rate of FHB infection on cultivar Apogee (a rapidly 
maturing and FHB-susceptible variety of wheat) spikelet florets. Inoculation of FG08-
pretreated spikelet florets with F. graminearum did not result in any of the FHB 
symptoms (chlorosis and curled spikes) that were noticeable within 4 days on non-
pretreated spikelet florets (Figure 16). Therefore, the attachment of the octyl group 
triggered the loss of the antibacterial activity of FG08, while instantly imparting to it a 
fungicidal activity. This definitely suggested a different mode of action of FG08. 
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Figure 15: FG08 suppression of wheat leaf infection after exposure to F. 
graminearum
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Figure 16: FG08 suppression of FHB disease in wheat spikelet florets
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b) Mechanism of action of FG08 
Aminoglycosides are known to kill bacteria by binding to the ribosome and 
inhibiting protein synthesis. However, studies with fluorescent dye SYTOX green 
demonstrated that FG08 exerts its antifungal activity by perturbation of the membrane 
function.
104
 Upon binding with nucleic acids, SYTOX green will fluoresce when excited 
at 450-490 nm. Unless the cell membrane is compromised, the dye does not have the 
ability to cross the membrane. When Mr. Sanjib Shrestha, a graduate student in Dr. 
Takemoto’s laboratory, performed the dye permeation experiment, it was found that 
FG08 rapidly influenced the dye permeability of C. albicans cells and F. graminaerum 
hyphae (10 minutes). In addition, FG08 increased the membrane permeability of C. 
albicans 12 times better than kanamycin B. Also, FG08 did not lyse more than 20% of 
erythrocytes at a concentration 10-fold higher than its fungal MIC. This suggests that 
FG08 does not act as a surface-active agent that non-specifically disrupts membranes. 
Aminoglycosides are polycationic at physiological conditions. They can then 
aggregate on the fungal cell membrane by electrostatic interaction with the anionic 
sphingolipids. Then, the lipophilic alkyl chain found on FG08 enabled it to insert itself 
into the membrane bilayer of the fungi and eventually form pores. Therefore, the C8 alkyl 
chain found in FG08 confers to it amphipatic properties. 
 
III.2.3. Optimization of FG08 
In light of the impressive antifungal activity of FG08, we decided to improve on 
its synthesis by preparing FG03. FG03 differs from FG08 by the hydroxyl group present 
at the 6´´ position (Figure 17). 
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a) Synthesis of FG03 
 Starting from the 1,3-diol 17,
102
 tritylation selectively protects the primary 
alcohol, leaving a free hydroxyl group at position 4 (Scheme 10). Alkylation of the 4-OH, 
followed by the acid-catalysed removal of the trityl group revealed the 6-OH in 
compound 20. Benzylation afforded the thiophenyl donor 21. Glycosylation of 2 and 21, 
followed by acetonolysis, gave 22. Staudinger reduction of the azide into amine, 
hydrogenation, and ion-exchange provided FG03 as a chloride salt. 
 
b) Antimicrobial activities of FG03 
While maintaining its non-antibacterial activity, FG03 was also found to be 
effective against a number of fungi (Table 2). In addition, it was even more active than 
FG08 against F. graminearum.  
 
 
 
 
 
 
Figure 17: Structures of FG08 and FG03 
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Scheme 10: Synthesis of FG03 
 
 
 
 
Table 2: MIC values of FG08 and FG03a
 
 
 MIC (µg/mL) 
Organism FG08 FG03 
Bacteria   
Escherichia coli TG1b 125-250 >500 
Staphylococcus aureus (ATCC25923)c 250 NDd 
Filamentous fungi   
Fusarium graminearum B-4-5A 31.3 7.8 
Pythium ultimum 15.6 62.5 
Curvularia brachyspora 31.3 31.3 
Bortrytis cinerea 
 
31.3 31.3 
Yeasts   
Rhodotorula pilimanae (ATCC26423) 7.8 62.5 
Candida albicans (ATCC10231) 31.3 62.5 
a 
Data obtained by Sanjib Shrestha 
b 
Gram-negative bacteria 
c 
Gram-positive bacteria 
d
 Not determined 
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The scale-up synthesis of FG03 by a chemoenzymatic approach was attempted in 
Dr. Takemoto’s laboratory (Scheme 11). Although unsuccessful, this approach required 
4-O-octyl-D-glucopyranoside 23 and neamine 12, both chemically synthesized in our 
laboratory. 
The synthesis of 23 started from compound 20. Treatment with N-
bromosuccinimide gave 35, whose hydrogenation provided 23 (Scheme 12). 
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Scheme 11: Proposed chemo-enzymatic synthesis of FG03 
 
 
 
 
Scheme 12: Synthesis of compound 23 
 
 
 
 
 
38 
 
 
III.2.4. Alkyl group mapping 
From the promising results of FG03 and FG08, which both have a linear C8 alkyl 
chain at the O-4´´ position, we decided to explore the effect of an octyl group at other 
positions, by synthesizing kanamycin B analogs FG05, FG06, FG07, FG09, FG10, and 
FG11. 
 
a) Synthesis of FG05 and FG06 (alkylation at O-6´´ position) 
The synthesis started with the regioselective ring opening of the known 
compound 26
107 
to obtain 27
108
 with a free hydroxyl group at the 6-position (Scheme 13). 
Alkylation using n-hexyl bromide and n-octyl bromide provided the thiophenyl donors 
28a and 28b, respectively. Glycosylation followed by acetonolysis gave 29a and 29b. 
Staudinger reaction, hydrogenation, and ion-exchange afforded FG05 and FG06, with C6 
and C8 alkyl chain at the O-6´´ position, respectively. 
 
b) Synthesis of FG07 (Alkylation at O-3´´ position) 
The synthesis started with the alkylation of diacetone-D-glucose 3 (Scheme 14). 
This gave the known compound 30,
109
 whose acid-catalysed hydrolysis and acetylation 
provided 31. Treatment of 31 with thiophenol in the presence of BF3-OEt2 gave 32. 
Through neighboring group participation (see Scheme 4), the acetyl group present at 
position 2 in 32 will favor the formation of a -anomer after glycosylation. However, a 2-
O-Bn will provide the required -glycosidic bond (see Scheme 6). Thus acetonolysis of 
32, followed by benzylation, afforded the thiophenyl donor 33, with a 2-O-Bn. 
Glycosylation of 2 and 33 in the presence of NIS and TMSOTf, followed by acetonolysis, 
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gave 34. Staudinger reaction, hydrogenation, and ion-exchange afforded FG07, which 
has a C8 alkyl chain at the 3´´ position.  
 
 
Scheme 13: Synthesis of FG05 and FG06 
 
 
 
c) Synthesis of FG09 (alkylation at O-2´´ position) 
The synthesis of FG09 started from the known compound 35
110
 (Scheme 15). 
Alkylation of the 2-OH gave 36, which upon treatment with Ac2O/AcOH/H2SO4 
provided 37. Reaction with thiophenol in the presence of BF3-OEt2 gave 38. 
Acetonolysis, followed by benzylation gave 39. Glycosylation of 2 and 39 in the presence 
of NIS and TMSOTf, followed by acetonolysis provided 40. Staudinger reaction, 
hydrogenation, and ion-exchange gave FG09 with the C8 alkyl chain at position 2´´. 
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Scheme 14: Synthesis of FG07 
 
 
 
d) Synthesis of FG10 and FG11 (alkylation at O-5 position) 
Benzylation at the 3´ and 4´ positions of the neamine derivative 14,
97
 followed by 
the acid-catalyzed cleavage of the cyclohexylidene protecting group gave the glycosyl 
acceptor 41
98
 (Scheme 16). Glycosylation of 41 with the known thiophenyl donors 42a
111
 
and 42b
112
 gave the compounds 43a and 43b, respectively. Both compounds have a free 
hydroxyl group at position 5 which will be alkylated to provide 44a and 44b, 
respectively. Staudinger reaction, hydrogenation, and ion-exchange afforded FG10 and 
41 
 
FG11, respectively, with the C8 alkyl chain at O-5 position. FG10 has a free hydroxyl 
(OH) group at position 3´´, while FG11 has an amino (NH2) group at position 3´´'.  FG10 
is thus an analog of FG08 and FG11 looks more to kanamycin B.  
 
 
 
Scheme 15: Synthesis of FG09 
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Scheme 16: Synthesis of FG10 and FG11 
 
e) Synthesis of FG12 and FG13 (alkylation at O-3´ and O-4´ positions, respectively) 
 
The neamine derivative 14
97
 has two free hydroxyl groups at position 3´ and 4´. 
Selective benzylation of 14 afforded a mixture of regioisomers (45a and 45b), along with 
the dibenzylated compound 46 (Scheme 17). The regioisomer 45a has a Bn group at the 
4´ position while the regioisomer 45b has the Bn group at the 3´ position. Attempts to 
separate 45a and 45b were unsuccessful. That mixture of 45a and 45b was then used as 
so. Alkylation of the free hydroxyl group in each regioisomer, followed by the acid-
43 
 
cleavage of the cyclohexylidene protecting group gave compounds 47a and 47b as an 
inseparable mixture. Glycosylation of the acceptors 47a and 47b with the donor 42a 
afforded 48a and 48b, which upon Staudinger reduction, hydrogenolysis, and ion 
exchange gave a mixture of FG12 and FG13.  
 
 
Scheme 17: Synthesis of FG12 and FG13 
 
 
f) Alkylation at O-4´´position confers optimum antifungal activity 
The effectiveness of the FG compounds was evaluated. The synthesized 
kanamycin B analogs were tested against the fungus F. graminearum. Microbroth 
44 
 
dilution assays performed in Dr. Takemoto’s laboratory revealed that FG08 and FG03, 
which both have an octyl group at the O-4´´ position, were the most active (Table 3). 
Indeed, FG08 and FG03 were found to inhibit the growth of F. graminearum at the 
minimum concentration of 7.8 µg/mL. 
 
 
Table 3: MIC values of FG compounds against F. graminearum
a 
 
Alkylation site Compound MIC 
(µg/mL) O-2'' FG09 20 
O-3'' FG07 62.5 
O-4'' FG03 (6''-OH) 7.8 
O-4'' FG08 (6''-H) 7.8 
O-6'' FG05 125 
O-6'' FG06 31.3 
O-5 FG10 (3''-OH) <500 
O-5 
 
FG11 (3''-NH2) 31.3 
O-3' & O-4' FG12 & FG13 ≤500 
                  a
 Data obtained by Yukie Kawasaki 
 
 On the other hand, the mixture of FG12 and FG13 showed no activity against F. 
graminearum. Since each compound constituted 50% of the mixture, we can therefore 
conclude that any of them, by itself, would be inactive against fungi. 
From the MIC values, it is therefore obvious that a linear C8 alkyl chain imparts 
optimum antifungal activity when it is attached at the O-4´´ position. 
 
III.3. Conclusion 
The presence of a linear C8 alkyl chain was found to induce an antibacterial to 
antifungal transformation to kanamycin B. Indeed, FG08, which has a linear C8 alkyl 
chain at the O-4´´ position, displayed impressive antifungal activity against a wide range 
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of crop disease pathogens (fungi). FG03, which also has a linear C8 alkyl chain at the O-
4´´ position, was synthesized with the intention to scale up the synthesis of FG08 by a 
chemo-enzymatic approach, but this route turned out unsuccessful. 
By employing glycodiversification, various sites in kanamycin B have 
successfully been alkylated to give new analogs. The antifungal activity results indicate 
the importance of the O-4´´ position. Indeed, FG08 and FG03, which are both alkylated 
at the O-4´´ position, were the most potent antifungal agents. 
In light of all these results, a structure-activity relationship can be drawn: 
attachment of a C8 alkyl chain at the O-4´´ position of kanamycin B converts this 
obsolete drug into a potent agro fungicide, with simultaneous loss of antibacterial 
activity.  
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CHAPTER IV 
SYNTHESIS AND ANTIBACTERIAL STUDY OF CATIONIC  
1,4-NAPHTHOQUINONE DERIVATIVES
c 
 
IV.1. Rationale 
With the growing rate of bacterial infections and antibiotic-resistance, there have 
been continuous calls for new antibacterial agents and natural products usually provide 
resourceful scaffolds. 1,4-naphthoquinone derivatives are ubiquitous in nature
47-51
 and 
display a wide range of biological activities.
52-56
 Our group has thus recently invested 
some efforts in the development of interesting molecules derived from 1,4-
naphthoquinone.
113-115
 We have synthesized a class of 1-alkyl-1H-naphtho[2,3-d][1,2,3] 
triazole-4,9-diones.
114
 These heterocyclic compounds combine two pharmacologically 
important moieties (1,4-naphthoquinone and 1,2,3-triazole), and were thus expected to 
exhibit unique biological activities. However, their poor solubility in aqueous media 
rendered them unavailable for biological testing. Nevertheless, methylation helped to 
solve this issue and led us to the discovery of a new series of anthraquinone analogs.
115
 
Many of these anthraquinone analogs happened to exhibit impressive antibacterial 
activity, notably against G+ bacteria, which might somewhat be related to the alkyl chain 
length at N-1 position.  
The aim of this project was therefore to optimize the production of 1-alkyl-1H-
naphtho[2,3-d][1,2,3]triazole-4,9-diones. In addition, we decided to synthesize a library 
of 1,3-dialkyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3] triazol-3-ium chloride 
                                                          
c
 Reprinted with permission from Fosso, M. Y.; Chan, K. Y.; Gregory, R.; Chang, C.-W. 
T. ACS Comb. Sci. 2012, 14, 231-235. Copyright © 2012, American Chemical Society. 
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salts, which are cationic 1,4-naphthoquinone derivatives. The study of their antibacterial 
activity will enable us to elucidate the structure-activity relationship that will result from 
the incorporation of various alkyl chains at both N-1 and N-3 positions. 
 
IV.2. Results and discussion 
IV.2.1. Optimization of the production of  
            1-alkyl-1H-naphtho[2,3-d]1,2,3]triazole-4,9-diones 
The reaction between 1,4-naphthoquinone and azido compounds has been known 
to occur either via a [2+3] cycloaddition,
915,116-118
 or through a Michael addition and/or  
oxidation process.
118,119
 Our group has recently reported the synthesis of  1-alkyl-1H-
naphtho[2,3-d][1,2,3]triazole-4,9-diones.
114
 This involves a thermodynamically-
controlled cycloaddition of 1,4-naphthoquinone 49 with alkyl azides, followed by an 
oxidation. Interestingly, this simple but versatile reaction was found to provide 
structurally diverse molecules, depending on the order of addition of the different 
reagents or the reaction conditions.  
For example, a one-pot/one-step [3+2] cycloaddition in which 49, sodium azide, 
and alkyl bromides were allowed to react in DMF provided our expected products 50-54 
(Scheme 18, Method A).
114
 This method also afforded the byproducts 2-alkyl-2H-
naphtho[2,3-d][1,2,3]triazole-4,9-diones 55-59. Although this protocol provided a one-
pot divergent synthesis of both classes of compounds in a unique and simple fashion, 
difficulty in separating them arose. Indeed, they displayed almost identical Rf values on 
TLC plate rendering it very difficult to scale up this protocol.  
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Scheme 18: Protocols for the preparation of compounds 50-54 
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To circumvent this problem, we decided to approach the synthesis of compounds 
50-54 in a one-pot/two-step fashion: the alkyl azides are first prepared in situ by reaction 
of sodium azide and alkyl bromides, before being allowed to react with 1,4-
naphthoquinone 49 (Scheme 18, Method B). To our surprise, this also gave the 
byproducts 2-alkylamino-1,4-naphthoquinones 60-64. Even though this class of 
compounds has been extensively studied for their pharmacological activities 
(antimycobaterial agents
120
 and inhibitors of coenzyme Q
57
), it was important to 
understand their formation. 
We suggested that the formation of 2-alkylamino-1,4-naphthoquinones 60-64  
results from the presence of an excess amount of alkyl bromides in the reacting vessel 
(Scheme 19). Following the initial cycloaddition of 49 with the alkyl azide, it is possible 
to have an SN
2
 nucleophilic substitution via N-3 of the triazoline adduct 65 toward the 
alkyl bromide. The unstable molecule 66 can undergo decomposition to give the 
intermediate species 67. Re-protonation of 67 affords the byproduct 2-alkylamino-1,4-
naphthoquinone. In this proposed mechanism, the remaining alkyl bromide from the 
previous step can actually function as a catalyst that facilitates the formation of 2-
alkylamino-1,4-naphthoquinone. 
In light of these results, we expected that a third alternative, a two-pot/two-step 
synthesis, whereby the alkyl azides were prepared separately and allowed to react with 49 
in another reacting vessel, would only provide our desired compounds 50-54 (Scheme 18, 
Method C). As expected, Method C generated only 50-54 with yields comparable to the 
other two methods (Table 4). More importantly, purification of compounds 50-54 
50 
 
produced in Method C was much easier as they could be isolated by precipitation in 
diethyl ether, avoiding the use of a column chromatography. 
 
 
 
Scheme 19: Mechanistic explanation for the formation of compounds 60-64 
 
 
 
 
Table 4: Comparison of the different methods for the preparation of compounds 50-54 
 
 
  Yield (%) 
Alkyl bromides 
1-alkyl-1H-naphtho[2,3-d] 
[1,2,3] triazole-4,9-dione 
Method  
Aa 
Method  
Bb 
Method 
C 
1 n-pentyl bromide  50a
 
41 53 40 
2 n-hexyl bromide  51 n.a. 66 49 
3 n-octyl bromide  52a 52 63 62 
4 n-decyl bromide  53a 64 33 54 
5 n-dodecyl bromide  54a 68 49 68 
a
: Ref. 114 
b
: obtained as inseparable mixtures of 1-alkyl-1H-naphtho[2,3-d] [1,2,3] triazole-4,9-dione and 
2-alkylamino-1,4-naphthoquinone.The yields of 50-54 are estimated from the integral ratio of the 
1
H NMR. 
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IV.2.2. Synthesis of novel cationic 1,4-naphthoquinone derivatives 
Our initial class of cationic 1,4-naphthoquinone derivatives was obtained by 
methylation at the N-3 position of the triazole motif of compounds 50-54.
115
 In order to 
investigate the effect of the chain length at N-3 position, we synthesized analogs with 
various chain lengths at both nitrogen atoms (N-1 and N-3) using alkyl triflates (ROTf) 
prepared in situ from the corresponding alcohol (a-f) (Scheme 20). After alkylation, the 
TfO
-
 anion was exchanged with Cl
-
 anion using ion-exchange resin to yield our library of 
cationic 1,4-naphthoquinone derivatives. This protocol enabled the parallel synthesis of 
24 novel 1,3-dialkyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium 
chloride salts. 
 
IV.2.3. Antibacterial study 
Similarly to the series of previously synthesized cationic anthraquinone 
analogs,
115
 each member of our library bears the structural scaffolds of naphthoquinone, 
cation and lypophilic alkyl chain, and was therefore expected to show similar biological 
activity.  
The 1,3-dialkyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d] [1,2,3]triazol-3-ium 
chloride salts were tested against E. coli (ATCC 25922, G-) and S. aureus (ATCC 25923, 
G+) using neomycin, kanamycin, vancomycin, amikacin and 
hexadecyltrimethylammonium bromide (HTB) as the controls. The MIC values 
determined in standard fashion using serial 2-fold dilutions are listed in Table 5. The 
results show that these cationic compounds are more active against G+ bacteria than G- 
52 
 
bacteria, which is consistent with the antibacterial profile of naphthoquinone
63
 and 
cationic antiseptic agents such as HTB and cetrimonium bromide.
121
 
For cationic 1,4-naphthoquinone derivatives with a methyl group at N-3 position, 
we had previously observed that the antibacterial activity against S. aureus slightly 
increased with the number of carbon atoms in the alkyl group at N-1, reaching a 
maximum with the octyl group and then decreasing as the chain length was extended to 
16 carbons.
115
  
The presence of a different alkyl group at N-3 was however found to have a 
profound influence on antibacterial activity (Figure 18a). In general, compounds with 
MIC values below or equal to 1 mg/mL against S. aureus were obtained when the total 
number of carbon atoms of the alkyl groups on both nitrogen atoms was between 9 and 
16. This synergistic effect of alkyl group suggests that overall lipophilicity is an 
important factor in the antibacterial activity. In fact, antiseptic agents with lipophilic alkyl 
chains have been noted for their ability to disrupt the bacterial membrane of S. aureus.
122
 
It should also be noted that those cationic antiseptic agents generally have a C12 or longer 
hydrophobic tail length. This new library therefore combines shorter-chain and longer-
chain compounds.  
On the other hand, no general trend could be deduced from the MIC values based 
on the chain length against E. coli suggesting that lipophilicity might not be a prerequisite 
for the antibacterial activity of this library against G- bacteria (Figure 18b). 
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1-alkyl-1H-
naphtho-triazole-
4,9-diones 
R Alcohol R' Product Yield (%) 
50 C5H11 
a C2H5 50a 80 
b C4H9 50b 53 
c C5H11 50c 64 
e C8H17 50e 74 
f C10H21 50f 58 
51 C6H13 
a C2H5 51a 82 
b C4H9 51b 95 
c C5H11 51c 62 
d C6H13 51d 90 
e C8H17 51e 88 
f C10H21 51f 39 
52 C8H17 
a C2H5 52a 51 
b C4H9 52b 99 
e C8H17 52e 29 
f C10H21 52f 81 
53 C10H21 
a C2H5 53a 99 
b C4H9 53b 87 
f C10H21 53f 93 
54 C12H25 
a C2H5 54a 99 
b C4H9 54b 93 
c C5H11 54c 99 
d C6H13 54d 88 
e C8H17 54e 52 
f C10H21 54f 99 
 
Scheme 20: Synthesis of cationic 1,4-naphthoquinone derivatives 
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Table 5: MIC values of cationic 1,4-naphthoquinone derivatives (μg/mL) 
 
Compound R R' E.coli S. aureus 
Neomycin B - - 8 1 
Kanamycin - - 4 1-2 
Vancomycin - - 64-125 0.5 
Amikacin - - 0.125 0.5 
HTB - - 1 0.5-1 
68a
 
C5H11 CH3 8-16 2 
50a C5H11 C2H5 ≥250 2-4 
50b C5H11 C4H9 ≥250 0.5 
50c C5H11 C5H11 ≥250 1 
50e C5H11 C8H17 32-64 0.125 
50f C5H11 C10H21 8-16 1-2 
69b C6H13 CH3 125-250 1-2 
51a C6H13 C2H5 125-250 1 
51b C6H13 C4H9 125-250 1 
51c C6H13 C5H11 125 1-2 
51d C6H13 C6H13 32-64 0.5-1 
51e C6H13 C8H17 4-8 0.5-1 
51f C6H13 C10H21 2 0.25-0.5 
70a
 
C8H17 CH3 16-32 0.032-0.064 
52a C8H17 C2H5 ≥250 0.25-0.5 
52b C8H17 C4H9 64 1-2 
52e C8H17 C8H17 ≥250 2-4 
52f C8H17 C10H21 32-64 1-2 
71a
 
C10H21 CH3 32 0.032 
53a C10H21 C2H5 ≥250 0.125-0.25 
53b C10H21 C4H9 64-125 0.25 
53f C10H21 C10H21 125-250 16-32 
72a
 
C12H25 CH3 16-32 0.064-0.125 
54a C12H25 C2H5 32 0.125 
54b C12H25 C4H9 ≥250 0.5-1 
54c C12H25 C5H11 125-250 0.25-0.5 
54d C12H25 C6H13 125 0.5-1 
54e C12H25 C8H17 125-250 2-4 
54f C12H25 C10H21 >250 16-32 
a
: Ref. 115; 
b
: Compound 69 was synthesized according to the protocol described in reference 115. 
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Figure 18: Effect of the alkyl chain length on the MIC values of the cationic 1,4-
naphthoquinone derivatives against (a) S. aureus and (b) E. coli 
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IV.3. Conclusion 
We have developed a new and improved protocol for the synthesis of 1-alkyl-1H-
naphtho[2,3-d][1,2,3]triazole-4,9-diones. To further investigate the effect of alkyl 
substitution at N-3 position, we constructed a library of 4,9-dioxo-4,9-dihydro-1H-
naphtho[2,3-d][1,2,3]triazol-3-ium chloride salts and tested them against a representative 
G+ and G- bacterium. When the total number of carbon atoms of the alkyl groups at both 
N-1 and N-3 ranged between 9 and 16, these cationic 1,4-naphthoquinone derivatives will 
exhibit nanomolar-level antibacterial activity against S. aureus, suggesting a synergistic 
effect of the alkyl group. However, they showed little or no activity against E. coli. 
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CHAPTER V 
CONCLUSIONS AND SIGNIFICANCE 
 
 
Aminoglycosides and 1,4-naphthoquinone derivatives are two classes of naturally 
occurring compounds that have long attracted interest due their important biological and 
pharmaceutical applications, earning them the title of “drug-productive scaffolds.”  
Aminoglycosides are clinically used antibiotics with a broad-spectrum of activity 
against Gram-negative and Gram-positive bacteria. However, the continuous emergence 
of bacterial resistance has seriously hampered their efficacy. While many efforts have 
been devoted to reviving their antibacterial activity, novel avenues have also been 
explored in the field of aminoglycosides. Their ability to bind to the ribosome has been 
exploited in the development of new therapeutic approaches to treat genetic diseases 
caused by premature nonsense mutations. Our laboratory has previously synthesized 
libraries of aminoglycosides and the bioactive screening of these libraries has enabled the 
identification of a lead compound, TC007, in the treatment of spinal muscular atrophy. 
By slightly modifying the original protocol, more TC007 was prepared and it was found 
to restore the functionality of the truncated and unstable SMN∆7 protein by allowing the 
incorporation of a near-cognate amino acid at the premature stop codon. 
Another screening of our libraries of aminoglycosides has revealed FG08, a 
kanamycin B analog, as a potential antifungal agent with application in agriculture. FG08 
was found to inhibit the growth of several pathogenic fungi that are responsible for a 
large number of crop diseases. In particular, FG08 was found to suppress Fusarium head 
blight, a crop disease that has incurred huge economic losses to the U.S. government. 
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More interesting, unlike other antibiotics used in plant disease control, FG08 did not 
show any activity against bacteria. As a result, FG08 will unlikely contribute to the 
transfer of bacterial resistance. The main chemical feature of FG08 that enabled it to 
“switch” from an antibacterial agent (kanamycin) to a fungicide was found to be the C8 
alkyl chain present at O-4´´position. Novel kanamycin B analogs were then synthesized 
to investigate the alkyl chain length and the position of its attachment that will confer 
optimum fungicidal activity. First, two different alkyl groups (n-butyl and n-dodecyl) 
were inserted at the O-4´´position of ring III, which was later on attached by regio- and 
stereoselective glycosylation at the O-6 position of neamine. Second, an n-octyl group 
was introduced at various positions of ring I (O-2´´, O-3´´, O-4´´, and O-6´´), ring II (O-
5), and ring III (O-3´ and O-4´) to afford seven additional kanamycin B analogs. A 
bioactive screening of these analogs allowed us to draw a SAR for the optimization of 
kanamycin B analogs as potential agro fungicides. 
Finally, a protocol was developed to improve the production of 1-alkyl-1H-
naphtho[2,3-d][1,2,3]triazole-4,9-diones and a library of cationic 1,4-naphthoquinone 
derivatives was synthesized. Unlike the previously reported one-pot/one-step [3+2] 
cycloaddition that gives an inseparable mixture of 1-alkyl-1H-naphtho[2,3-
d][1,2,3]triazole-4,9-diones and its byproduct,
115
 a two-pot/two-step method provided 
only the desired compound upon precipitation in diethyl ether, avoiding the use of a 
column chromatography. This enabled the facile synthesis of a library of cationic 1,4-
naphthoquinone derivatives whose several members were found to exhibit antibacterial 
activity in the nanomolar range. More importantly, these compounds were more active 
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against Gram-positive bacteria than Gram-negative. They could be of great importance 
when antibiotics with narrow-spectrum activity are required. For example, Clostrodium 
difficile is a Gram positive bacterium responsible for clodistrium difficile infection (CDI), 
which is a severe inflammation of the colon. CDI is usually observed following surgery, 
when the gut flora has been eradicated by the use of antibiotics. The human body lacking 
the ability to defend itself, invasion of C. difficile is now inevitable, unless a drug with 
specific activity against Gram-positive bacteria is used.  
This research has therefore contributed to the investigation of new applications of 
aminoglycosides, and developed novel cationic 1,4-naphthoquinone derivatives. 
However, more work is still to be done to get as close as possible to the development of a 
new drug. With the finding of the conversion of the antibacterial kanamycin B to an agro 
fungicide as a result of the attachment of a C8 alkyl chain at the 4´´ position, an 
appropriate 4-O-octyl glucopyranose derivative needs to be developed for a facile 
chemoenzymatic synthesis of FG08 or FG03. In addition, novel cationic 1,4-
naphthoquinone derivatives with aryl groups at N-1 position could be synthesized. 
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CHAPTER VI 
EXPERIMENTAL SECTION 
 
 
Chemical reagents and chromatography solvents were purchased from Aldrich 
Chemical Co. or Acros Chemical Co. and were used without purification unless 
otherwise noted. Dichloromethane was freshly distilled from calcium hydride. Pyridine 
and triethylamine were stored over 4 Å molecular sieves. Column chromatographic 
purifications were carried out on silica gel 230x450 mesh, Sorbent Tech. Analytical TLC 
was performed on Sorbent Technologies silica gel glass TLC plates. Visualization was 
accomplished with UV light (254 nm) followed by staining with diluted sulfuric acid (5% 
in methanol) solution and heating. 
Proton magnetic resonance spectra were recorded using JEOL 300 or Bruker 
ARX 400 spectrometers. Chemical shifts were reported as parts per million (ppm) 
downfield from tetramethylsilane in δ unit and coupling constants were given in cycles 
per seconds (Hz). Signal multiplicities were indicated by s (singlet), d (doublet), t 
(triplet), q (quartet), and m (multiplet). 
13
C NMR spectra were obtained using JEOL 300 
at 75 MHz, or Bruker ARX 400 at 100 MHz. Routine 
13
C NMR spectra were fully 
decoupled by broad-band WALTZ decoupling. All NMR spectra were at ambient 
temperature. High-resolution fast-atom bombardment (HRFAB), high-resolution 
MALDI, chemical ionization (CI), atmospheric pressure chemical ionization (APCI) or 
electrospray ionization (ESI) were provided by the Mass Spectrometry Facilities, 
University of California, Riverside. 
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General Procedure for Aminoglycoside Treatment of SMA (performed in Dr. 
Lorson’s laboratory). 3,813 SMA type I patient fibroblasts cells were plated on cover 
slips and grown in Dulbeccos’s modified Eagle’s medium (DMEM) containing 10% (v/v) 
fetal bovine serum and antibiotics for 24 h. Cells were washed three times with 
phosphate-buffered saline (PBS) and re-fed with DMEM containing the aminoglycoside 
diluted to the indicated concentration. In prolonged experiments, the medium containing 
freshly diluted aminoglycoside was changed every 24 h for the indicated duration (up to 
96 h). For cells used in Western blot analysis, cells were plated at ~80% confluence in 
six-well dishes and treated for 48 h. Fresh drug-containing media was replaced every 24 
h, diluted to 100 μg/mL. Cells were initially identified by DAPI staining, not by the 
presence or the absence of SMN and gems. Only after obtaining a field of view, the 
SMN/FTIC channel was observed. The DAPI field was done randomly across a large 
number of treated cells, providing an unbiased assessment of gem numbers throughout 
the cell population. 
General Procedure for Mice and TC007 Treatment (performed in Dr. Lorson’s 
laboratory). All animal experiments were carried out in accordance with protocols 
approved by the Animal Care and Use Committee of the University of Missouri. Mice 
were genotyped and litters excluded. TC007 was initially resuspended in distilled water, 
further diluted in PBS, and administered by subcutaneous injection (10 μL/gram of body 
weight) on post-natal days 2 through 15. PBS (vehicle) was injected as a negative control. 
To assess gross motor function, righting reflex was measured starting at post-natal day 5.  
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General Procedure for MIC Determination. A solution of selected bacteria was 
inoculated in the Trypticase Soy broth at 35 
o
C for 1-2 h. The bacteria concentration was 
found and diluted with broth, if necessary, to an absorption value of 0.08 to 0.1 at 625 
nm. The adjusted inoculated medium (100 µL) was diluted with 10 mL of broth and then 
applied to a 96-well microtiter plate (50 µL). A series of solutions (50 µL each in 2-fold 
dilution) of the tested compounds was added to the testing wells. The 96-well plate was 
incubated at 35 
o
C for 12-18 h. The minimum inhibitory concentration (MIC) is defined 
as the minimum concentration of compound needed to inhibit the growth of bacteria. The 
MIC results are repeated at least three times. 
General Procedure for Leaf Infection Assay (performed by Ms. Yukie 
Kawasaki, a graduate student of Dr. Jon Takemoto. All the figures/data related to leaf 
infection assay remain her sole propriety). Suspensions of F. graminearum macronidia 
(2.0x10
4
 mL
-1
) were prepared in sterile solution of 0.25% (wt vol
-1
) agar and 0.20% (by 
volume) of Tween 20 and mixed with equal volumes of aminoglycoside made in the 
same solution. 
FHB Disease Suppression (performed by Ms. Yukie Kawasaki, a graduate 
student of Dr. Jon Takemoto. All the figures/data related to FHB disease suppression 
remain her sole propriety). Rapid-maturing cultivar Apogee was grown for 5-6 weeks in a 
greenhouse to the flowering stage. Florets (one per spikelet) were treated with a solution 
of aminoglycoside at the indicated concentration, and then inoculated with suspension of 
F. graminearum macroconidia (10 µL, 10
5
 conidia mL
-1
). After 4 days, the spikelets were 
visually inspected for disease symptoms (chlorosis, spikelet curling, and dehydration). 
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General Procedure for O-Alkylation of Sugars. To a solution of starting 
material in anhydrous DMF, alkyl bromide (2.0 equivalents), NaH (2.0 equivalents), and 
catalytic amount of TBAI were added. The reaction was stirred overnight. When 
complete, the reaction was quenched by addition of MeOH (5 mL) and was slowly 
poured into a mixture of ice and EtOAc. The aqueous layer was extracted with EtOAc. 
The combined organic layers were washed with 1 N aqueous HCl, water, saturated 
aqueous NaHCO3 and brine, and then dried over solid Na2SO4. After removal of the 
solvent and purification with gradient column chromatography (hexane:EtOAc = 100:0 to 
60:40), the product was obtained. 
General Procedure for the Glycosylation using Thiophenyl donor, and 
Hydrolysis. A solution of glycosyl donor, neamine derivative (1.2 equivalents), and 
activated powder 4 Å molecular sieve was stirred at room temperature for 2 h in 12 mL 
of a mixed anhydrous solution Et2O:CH2Cl2 = 3:1. The mixture was cooled to -70 
o
C and 
N-iodosuccinimide (1.2 equivalents) was quickly added. After the temperature has 
warmed up to -40 
o
C, trifluoromethanesulfonic acid (0.15 equivalents) was added. The 
solution was stirred at low temperature till the complete consumption of the glycosyl 
donor. The reaction mixture was quenched by addition of solid NaHCO3, Na2S2O3, and 
Na2SO4. After being stirred for 15 minutes, the reaction mixture was filtered through 
celite. The residue was washed thoroughly with EtOAc. After removal of the solvents, 
the crude product was purified with gradient column chromatography. The glycosylated 
compounds were often mixed with inseparable impurities, and were therefore fully 
characterized after hydrolysis. The glycosylated product was dissolved in THF (1 mL) 
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and MeOH (5 mL), and 1M NaOMe in MeOH (0.5 mL) was added. The mixture was 
stirred at room temperature until TLC analysis indicated completion of the reaction 
(about 30 minutes). The reaction was neutralized with Amberlite IR-120 (H
+
), and 
filtered through celite. After removal of the solvents, the crude product was purified with 
gradient column chromatography (Hexane:EtOAc = 100:0 to 50:50) to afford the 
expected product. 
General Procedure for Cycloaddition of 1,4-Naphthoquinone 
Method A. is described in ref 114. 
Method B. A solution of NaN3 (~0.1 g) and alkyl bromide (2 equivalents) in DMF (10 
mL) was stirred at 80 
o
C for one day in a sealed vial. Then naphthoquinone (2 
equivalents) was added and the mixture was heated for another day at 110 
o
C. The 
solvent was evaporated and the crude product was purified by column chromatography 
(eluted from hexane:EtOAc = 100:0 to 50:50) to afford a mixture containing both 1-
alkyl-1H-naphtho[2,3-d]triazole-4,9-diones and 2-alkylamino-1,4-naphthoquinones. The 
2-alkylamino-1,4-naphthoquinones were recovered after N-3 alkylation. 
Method C. A solution of alkyl azide (~0.3 g), which was obtained using the method 
described in reference 124, and naphthoquinone (2 equivalents) in DMF (10 mL) was 
stirred at 110 ˚C overnight in a sealed vial. The solvent was evaporated and cold diethyl 
ether (50 mL) was added. The solid that precipitated was collected by filtration through a 
Hirsh funnel and washed with more diethyl ether to afford the expected product as a pale 
brown solid. 
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General Procedure for N-3 Alkylation. The alcohol (2 equivalents) and pyridine 
(4 equivalents) were dissolved in anhydrous toluene (10 mL) and cooled in an ice-water 
bath before Tf2O (4 equivalents) was slowly added. The mixture was stirred at 0 
o
C for 2 
h and the triazole (0.11 g, 1 equivalent) was then added. This mixture was then refluxed 
at 110 
o
C for 6-8 h. After completion of the reaction, the solvent was removed and the 
crude product was purified by column chromatography (eluted with 300 mL 
Hexane:EtOAC = 50:50, 200 mL pure EtOAc, and finally 100 mL EtOAc:MeOH = 
80:20)  to afford the expected product, which was then eluted through a small column 
packed with Dowex 1x8 (Cl
-
) resin for ion exchange.  
Hexaazido-hepta-O-benzyl Neomycin (1).
82
 NaN3 (54.8 g, 842.2 mmol) was 
first dissolved with distilled water (75 mL) in a 1L round-bottomed flask. 
Dichloromethane (125 mL) was then added and the flask was transferred in an ice-water 
bath. Tf2O (28.4 mL, 168.5 mmol) was slowly added and the mixture was stirred at low 
temperature. Two hours later, the reaction mixture was transferred into a 1L separatory 
funnel and a saturated aqueous NaHCO3 solution was added. The funnel was shaken to 
release CO2 gas and the CH2Cl2 phase was separated. The aqueous phase was extracted 
with an additional 75 mL CH2Cl2. The organic layers were then combined and washed 
with saturated NaHCO3 solution until no more gas was produced. This freshly prepared 
dichloromethane solution of triflic azide was slowly added to a mixture of neomycin 
trisulfate (10.0 g, 14.04 mmol), CuSO4.5H2O (0.35 g, 1.40 mmol), K2CO3 (15.5 g, 112.3 
mmol) in H2O (150 mL) and MeOH (300 mL). The mixture was stirred at room 
temperature overnight until TLC analysis showed complete reaction. The solvent was 
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then removed under reduced pressure, and the residue was redissolved in EtOAc. The 
filtrate obtained following filtration through a celite bed was subsequently extracted with 
1N aqueous HCl, saturated aqueous NaHCO3, water and brine. The organic layer was 
dried over Na2SO4, filtered and concentrated under reduced pressure to provide a 
greenish crude product. After being dried under vacuum pump for a few hours, the crude 
product (14.07 g, 18.3 mmol) was dissolved in DMF (100 mL), and BnBr (32.8 mL, 
274.1 mmol) and a catalytic amount of TBAI were added. The mixture was then 
transferred in an ice-water bath and NaH (11.0 g, 274.1 mmol) was slowly added.  When 
TLC analysis performed the following day indicated completion, the reaction was 
quenched with MeOH (20 mL) and poured over ice. The mixture was diluted with 
EtOAc, extracted with 1N aqueous HCl, saturated aqueous NaHCO3, water and brine, 
dried over Na2SO4, filtered, and concentrated. Purification of the crude product by 
gradient column chromatography (hexane:EtOAc = 100:0 to 50:50) provided 1 (7.44 g, 
5.3 mmol, 38% from neomycin sulfate). 
1,3,2´,6´-Tetraazido-6,3´,4´-tri-O-benzyl Neamine (2).
82
 Compound 1 (7.44 g, 
5.3 mmol) was dissolved in CH3CN (100 mL) and CuCl2.2H2O (1.81 g, 10.6 mmol) was 
added. The mixture was stirred at 80 
o
C overnight until TLC analysis showed completion 
of the reaction. The solvent was then removed under reduced pressure. The residue 
obtained was redissolved in EtOAc and filtered through a celite bed. The filtrate was then 
extracted with water and brine, dried over Na2SO4, filtered, and concentrated. 
Purification by gradient column chromatography (hexane:EtOAc = 100:0 to 20:80) 
provided 2 (2.10 g, 3.0 mmol, 57%). 
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1,2:5,6-Di-O-isopropylidene-α-D-allofuranose (4).83 To a sealed round-
bottomed flask containing anhydrous CH2Cl2 (400 mL) at -78 
o
C, oxalyl chloride (5.03 
mL, 57.6 mmol) and anhydrous DMSO (8.2 mL, 115.3 mmol) were added dropwise. 
When the temperature warmed up to -65 
o
C, a solution of diacetone-D-glucose 3 in 
anhydrous CH2Cl2 (100 mL) was added, and the reaction was allowed to stir until the 
temperature reaches -45 
o
C. At that moment, anhydrous Et3N (32.3 mL, 230.6 mmol) was 
added and the reaction mixture was stirred until room temperature. The mixture was 
diluted with CH2Cl2 and washed with 1N aqueous HCl, pH 7 buffer (3 times), and brine. 
The organic layer was dried over Na2SO4, filtered, and concentrated. The crude product 
obtained was then dissolved in anhydrous MeOH and the solution was cooled down to 0 
o
C. NaBH4 (4.36 g, 115.3 mmol) was then slowly added and the reaction was allowed to 
stir overnight till room temperature. The reaction was quenched by adding HCl dropwise 
until the solution reaches pH 8. Removal of the solvents gave a syrup-like residue that 
was diluted with EtOAc. Filtration through layers of silica gel and celite provided a 
solution that was concentrated and purified by gradient column chromatography 
(hexane:EtOAc = 100:0 to 40:60) to afford 4 (4.62 g, 17.7 mmol, 46%). 
3-Azido-3-deoxy-1,2:5,6-di-O-isopropylidene-α-D-glucopyranose (5).84 To a 
solution of 4 (4.59 g, 17.6 mmol) in anhydrous CH2Cl2 (100 mL), pyridine (4.2 mL, 51.1 
mmol) was added and the mixture was cooled down to 0 
o
C in an ice-water bath. Tf2O 
(7.5 mL, 44.1 mmol) was then added dropwise and the reaction was allowed to stir for 2 
h, during which time the temperature reached 20 
o
C. The reaction mixture was diluted 
with CH2Cl2 and washed with water, saturated aqueous NaHCO3 (twice), and brine. The 
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organic layer was dried over Na2SO4, filtered, and concentrated. The crude triflate was 
added to a solution of NaN3 (3.44 g, 52.9 mmol) in DMF (50 mL) and the reaction was 
stirred at room temperature overnight until TLC analysis confirmed completion of the 
reaction. The solvent was then removed to afford a residue that was dissolved in EtOAc.  
The organic layer was washed with water and brine, dried over Na2SO4, filtered, and 
concentrated. Purification by gradient column chromatography (hexane:EtOAc = 100:0 to 
20:80) provided 5 (3.68 g, 12.9 mmol, 73%).  
1,2,4,6-Tetra-O-acetyl-3-azido-3-deoxy-D-glucopyranose (6).
85 
A solution of 5 
(4.40 g, 15.4 mmol) in 150 mL of a mixed solution of AcOH/TFA/H2O (80/1/19) was 
stirred at 55 
o
C overnight. When TLC analysis indicated completion of the reaction, the 
solvents were removed. After being dried in vacuo for a few hours, the crude product was 
dissolved in Ac2O (50 mL) and TFA (5 mL), and the mixture was stirred at room 
temperature overnight. Solid NaHCO3 was then added to neutralize the excess acid. 
EtOAc was added to dilute the solution and the organic layer was washed with water, 
saturated aqueous NaHCO3 (3 times), and brine. The organic layer was then dried over 
Na2SO4, filtered, and concentrated. Purification by gradient column chromatography 
(hexane:EtOAc = 100:0 to 40:60) provided 6 (5.42 g, 14.5 mmol, 94%) as a mixture of 
α/β anomers in a 1/1 ratio. 
2,4,6-Tri-O-acetyl-3-azido-3-deoxy-D-glucopyranose (7).
86 
To a solution of 6 
(0.37 g, 0.99 mmol) in anhydrous DMF (5 mL) was added hydrazine acetate (0.11 g, 1.2 
mmol). The reaction mixture was stirred at room temperature for 6 h when TLC analysis 
indicated completion of the reaction. The reaction mixture was then filtered through a 
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short column packed with layers of silica gel and celite. The column was eluted 
thoroughly with EtOAc. After removal of the solvents, the crude product was purified by 
gradient column chromatography (hexane:EtOAc = 100:0 to 0:100) to afford 7 (0.32 g, 
0.97 mmol, 98%) as a mixture of α/β anomers in a 1/1 ratio. 
3-Azido-2,4,6-tri-O-acetyl-3-deoxy-α-D-glucopyranosyl trichloroacetimidate 
(8).
87
 To a solution of 7 (0.66 g, 2.0 mmol) and trichloroacetonitrile (1.0 mL, 10.0 mmol) 
in anhydrous CH2Cl2, DBU (0.08 mL, 0.50 mmol) was added dropwise. The solution was 
stirred at room temperature until TLC analysis indicated completion of the reaction, 
sometimes as fast as 10 minutes. Then charcoal was added to the reaction mixture. This 
was then filtered through a short column packed with celite and the column was 
thoroughly eluted with EtOAc. After removal of the solvents, the crude product was 
loaded in a column that has been pretreated with triethylamine. Purification by gradient 
column chromatography (hexane:EtOAc = 100:0 to 50:50) provided 8 (0.63 g, 1.3 mmol, 
66%). This was kept in the fridge until needed to prevent it from degrading at room 
temperature. 
5-O-(3´´-Azido-2´´,4´´,6´´-tri-O-acetyl-3-deoxy-β-D-glucopyranosyl)-1,3,2´,6´-
tetrazido-6,3´,4´-tri-O-benzyl neamine (9).
87 
A solution of neamine derivative 2 (0.20 g, 
0.29 mmol), glycosyl trichloroacetimidate 8 (0.16 g, 0.34 mmol), and activated powder 4 
Å molecular sieve was stirred in anhydrous diethyl ether (10 mL) at room temperature for 
2 h, then cooled to -50 
o
C. BF3-OEt2 (0.05 mL) was then added. The solution was stirred 
till the complete consumption of 2. The reaction mixture was quenched by the addition of 
powder NaHCO3. After being stirred for 15 minutes, the reaction mixture was filtered 
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through celite. The residue was washed thoroughly with EtOAc. After removal of the 
solvents, the crude product was purified with gradient column chromatography 
(hexane:EtOAc = 100:0 to 50:50) to afford 9 (0.22 g, 0.22 mmol, 76%). 
 
5-O-(3-Amino-3-deoxy-β-D-glucopyranosyl)neamine (TC007).87 A solution of 
9 (0.33 g, 0.33 mmol) and K2CO3 (0.41 g, 2.94 mmol) was stirred in MeOH (10 mL) at 
room temperature overnight until TLC analysis indicated completion of the reaction. The 
solvent was removed, and the reaction mixture was diluted with EtOAc and filtered 
through a short column packed with layers of silica gel and celite. The column was eluted 
with EtOAc and MeOH. After removal of the solvents, the crude product was dissolved 
in THF (5 mL) and the solution was transferred in a reaction flask equipped with a reflux 
condenser. Then H2O (0.6 mL) and PMe3 (1M in THF, 1.36 mL, 1.36 mmol) were added. 
The reaction mixture was stirred at 50 
o
C for 2 h until completion of the reaction. 
Removal of the solvents afforded a crude product that was dissolved in 5 mL of degassed 
AcOH/H2O (1/4). Then a catalytic amount of Pd(OH)2/C (20% Degussa type) was added 
and the reaction mixture was further degassed. The reaction mixture was then stirred at 
room temperature under atmospheric H2 pressure for one day. The reaction mixture was 
then filtered through celite. The residue was washed with water, and the combined 
solutions were concentrated, affording a crude product that was eluted through an ion-
exchange column packed with Dowex 1X8 resin (Cl
-
 form). Removal of the solvents 
afforded TC007 as a chloride salt (136.3 mg, 0.20 mmol, 61% over 4 steps).  
1,3,2´,6´-Tetraazidoneamine (13).
101
 NaN3 (50.0 g, 768.9 mmol) was first 
dissolved with distilled water (46 mL) in a 1L round-bottomed flask. Dichloromethane 
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(77 mL) was then added and the flask was transferred in an ice-water bath. Tf2O (26.0 
mL, 153.8 mmol) was slowly added and the mixture was stirred at low temperature. Two 
hours later, the reaction mixture was transferred into a 1L separatory funnel and saturated 
aqueous NaHCO3 was added. The funnel was shaken to release CO2 gas and then the 
CH2Cl2 phase was separated. The aqueous phase was extracted with an additional 75 mL 
CH2Cl2. The organic layers were then combined and washed with saturated aqueous 
NaHCO3 solution until no more gas was produced. (Even though an explosion never 
happened whenever I had to prepare triflic azide, extra precaution should be taken 
throughout its synthesis as it is known to be very explosive).This freshly prepared 
dichloromethane solution of triflic azide was slowly added to a mixture of neamine 
hydrochloride 12 (9.0 g, 19.2 mmol), CuSO4.5H2O (0.48 g, 1.92 mmol), and K2CO3 (21.2 
g, 153.8 mmol) in H2O (150 mL) and MeOH (300 mL). The mixture was stirred at room 
temperature overnight until TLC analysis showed complete reaction. The solvent was 
then removed under reduced pressure, and the residue was redissolved in EtOAc. The 
filtrate obtained following filtration through a celite bed was subsequently extracted with 
1N aqueous HCl, saturated aqueous NaHCO3, water and brine. The organic layer was 
dried over Na2SO4, filtered and concentrated. Purification with gradient column 
chromatography (hexane:EtOAc = 100:0 to 0:100) afforded 13 (4.26 g, 10.0 mmol, 52%). 
1,3,2´,6´-Tetraazido-5,6-O-cyclohexylideneneamine (14).
97 
To a solution of 13 
(7.95 g, 18.6 mmol) and p-toluenesulfonic acid monohydrate (1.77 g, 9.32 mmol) in 
anhydrous CH3CN (100 mL), cyclohexanone dimethyl ketal (12.8 mL, 83.9 mmol) was 
added, and the mixture was stirred overnight at room temperature. The reaction mixture 
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was quenched by addition of Et3N (2.6 mL) and was concentrated. The residue obtained 
was redissolved in EtOAc, washed with water and brine, dried over Na2SO4, and 
concentrated. Purification with column chromatography provided 14 (4.8 g, 9.5 mmol, 
51%). 
1,3,2´,6´-Tetraazido-3´,4´-di-O-acetylneamine (10).
97 
To a solution of 14 (3.20 
g, 6.32 mmol) in anhydrous CH2Cl2 (50 mL), Et3N (6.2 mL, 44.3 mmol) and DMAP 
(0.31 g, 2.53 mmol) were slowly added, followed by Ac2O (3.0 mL, 32.6 mmol). The 
reaction was stirred at room temperature for 3 h. When complete, the reaction mixture 
was quenched with saturated aqueous NaHCO3 and extracted with EtOAc. The organic 
layer was washed with 1N aqueous HCl, water, saturated aqueous NaHCO3, brine, and 
dried over solid Na2SO4. After removal of the solvent, a brownish, oily crude product 
was obtained, to which 80 mL of a mixed solution of dioxane:H2O = 1:1 was added, 
followed by 50 mL glacial acetic acid. The resulting mixture was refluxed at 60~65
o
C 
overnight. When complete, the reaction mixture was quenched with saturated aqueous 
NaHCO3 and extracted with EtOAc. The organic layer was washed with 1N aqueous 
HCl, water, saturated aqueous NaHCO3, brine, and dried over solid Na2SO4. After 
removal of the solvent followed by purification with a gradient column chromatography 
(hexane:EtOAc = 100:0 to 40:60), 10 was obtained (2.03 g, 4.0 mmol, 63%). 
Phenyl 4,6-O-(phenylmethylene)-1-thio-β-D-glucopyranoside (16).102 To a 
solution of 15 (10.0 g, 22.7 mmol) in anhydrous MeOH (300 mL), 5 mL of a 1M solution 
of NaOMe in MeOH was added and the mixture was stirred at room temperature for 2 h. 
When complete, the reaction was quenched by adding Amberlite IR 120 H
+ 
 resin to the 
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mixture, followed by filtration through celite and concentration of the filtrate. The crude 
product obtained was diluted in anhydrous DMF (50 mL), and TsOH.H2O (2.23 g, 11.7 
mmol) and benzaldehyde dimethyl acetal (3.53 mL, 23.4 mmol) were added. The reaction 
flask was then attached to a rotavapor and rotated at 60 
o
C for 1 h. The temperature of the 
water bath was then raised to 100 
o
C and most of the DMF was removed. The reaction 
mixture was cooled down to room temperature and saturated aqueous NaHCO3 (60 mL) 
was added. Lots of white precipitates were formed. The solution was then stirred at 90 
o
C 
and cooled down again to room temperature. The solids were filtered through a Buchner 
funnel, washed with plenty of water, and dried under reduced pressure to give 16 (7.4 g, 
20.4 mmol, 90%). 
Phenyl 2,3-di-O-benzyl-1-thio-β-D-glucopyranoside (17).102 To a solution of 16 
(2.24 g, 6.2 mmol) in DMF (40 mL), BnBr (3.0 mL, 24.9 mmol) and a catalytic amount 
of TBAI were added. The mixture was then transferred in an ice-water bath and NaH 
(1.00 g, 24.9 mmol) was slowly added.  When TLC analysis performed the following day 
indicated completion, the reaction was quenched with MeOH (5 mL) and poured over 
ice. The mixture was diluted with EtOAc. The organic layer was washed with 1N 
aqueous HCl, saturated aqueous NaHCO3, water and brine, dried over Na2SO4, filtered, 
and concentrated. The obtained crude product was dissolved in 30 mL of a mixed 
solution of MeOH:H2O = 1:1, and p-toluenesulfonic acid monohydrate (0.59 g, 3.1 
mmol) was added. The reaction mixture was stirred at room temperature overnight. When 
complete, the reaction was quenched by addition of Et3N (1.3 mL) and concentrated. The 
residue obtained was redissolved in EtOAc, washed with water and brine, dried over 
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Na2SO4, and concentrated. Purification with gradient column chromatography 
(hexane:EtOAc = 100:0 to 50:50) provided 17 (1.29 g, 2.9 mmol, 46%). 
Phenyl 2,3-di-O-benzyl-6-deoxy-1-thio-β-D-glucopyranoside (18).103 To a 
solution of 17 (5.13 g, 11.3 mmol) in anhydrous pyridine was slowly added TsCl (2.59 g, 
13.6 mmol) at 0 
o
C. The reaction mixture was stirred overnight allowing the reaction to 
warm to room temperature. After completion of the reaction, the reaction mixture was 
extracted with EtOAc. The combined organic layer was washed with aqueous 1 N HCl (3 
times), saturated aqueous NaHCO3, and brine, and dried over Na2SO4. After removal of 
the solvent, the tosylated crude product was dissolved in anhydrous THF (100 mL) and 
LiAlH4 (0.99 g, 26.0 mmol) was added. The reaction was stirred at room temperature 
overnight and then refluxed for 2 h. When complete, the reaction mixture was quenched 
by slow addition to ice then filtered through celite. The filtered residue was eluted with 
more EtOAc. The combined organic layers were washed with 1 N HCl, water, saturated 
aqueous NaHCO3 and brine, and dried over Na2SO4. Removal of the solvent followed by 
purification with gradient column chromatography (hexane: EtOAc = 90:10 to 40:60) 
afforded 18 (2.17 g, 4.97 mmol, 44%). 
Phenyl 2,3-di-O-benzyl-6-deoxy-4-O-n-butyl-1-thio-β-D-glucopyranoside 
(11a). Please refer to the general procedure for O-alkylation of sugars. Compound 11a 
was obtained with 72% yield.
 1
H NMR (CDCl3, 400 MHz) δ 7.2 - 7.8 (m, 15H), 5.01 (d, J 
= 10.3 Hz, 1H), 4.9 - 5.0 (m, 2H), 4.85 (d, J = 10.3 Hz, 1H), 4.77 (d, J = 9.8 Hz, 1H, H-
1), 3.9 (m, 1H, H-4), 3.7 (m, 2H), 3.57 (dd, J = 9.0, 9.5 Hz, 1H, H-2), 3.4 - 3.5 (m, 1H, 
H-5), 3.13 (t, J = 9.2 Hz, 1H, H-3), 1.6 - 1.7 (m, 2H), 1.48 (d, J = 6.1 Hz, 3H, H-6), 1.4 - 
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1.6 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H);
 13
C NMR (CDCl3, 100 MHz) δ 138.9, 138.5, 134.3, 
132.2 (2 carbons), 129.2 (2 carbons), 128.7 (4 carbons), 128.5 (2 carbons), 128.1 (3 
carbons), 128.0, 127.7, 87.7, 86.2, 84.1, 81.5, 76.1 (2 carbons), 75.8, 73.6, 32.9, 19.7, 
18.5, 14.3; ESI/APCI calcd for C30H36O4SNa ([M+Na]
+
) m/z 515.2232; measured m/z 
515.2231. 
Phenyl 2,3-di-O-benzyl-6-deoxy-4-O-n-octyl-1-thio-β-D-glucopyranoside 
(11b).
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Please refer to the general procedure for O-alkylation of sugars. Compound 11b 
was obtained with 63% yield. 
Phenyl 2,3-di-O-benzyl-6-deoxy-4-O-n-dodecyl-1-thio-β-D-glucopyranoside 
(11c).
 
Please refer to the general procedure for O-alkylation of sugars. Compound 11c 
was obtained with 64% yield.
 1
H NMR (CDCl3, 400 MHz) δ 7.3 - 7.7 (m, 15H), 5.0 (m, 
3H), 4.83 (d, J = 10.3 Hz, 1H), 4.74 (d, J = 9.7 Hz, 1H, H-1), 3.9 (m, 1H, H-4), 3.7 (m, 
2H), 3.4 - 3.6 (m, 2H), 3.12 (t, J = 9.2 Hz, 1H, H-3), 1.6 - 1.7 (m, 2H), 1.46 (d, J = 6.1 
Hz, 3H, H-6), 1.4 (m, 18H), 0.99 (t, J = 6.6 Hz, 3H);
 13
C NMR (CDCl3, 100 MHz) δ 
138.9, 138.5, 134.3, 132.1 (2 carbons), 129.2 (2 carbons), 128.7 (4 carbons), 128.5 (2 
carbons), 128.1 (3 carbons), 127.9, 127.7, 87.7, 86.8, 84.0, 81.4, 76.1 (2 carbons), 75.7, 
73.9, 32.2, 30.8, 30.0 (2 carbons), 29.9 (2 carbons), 29.8, 29.7, 26.5, 23.0, 18.4, 14.5; 
ESI/APCI calcd for C30H36O4SNa ([M+Na]
+
) m/z 627.3484; measured m/z 627.3478. 
6-O-(2,3-Di-O-benzyl-6-deoxy-4-O-n-butyl-D-glucopyranosyl)-1,3,2´,6´-
tetraazidoneamine (19a). Please refer to the general procedure for glycosylation using 
thiophenyl donor, and hydrolysis. Compound 19a was obtained with 71% yield. 
1
H NMR 
(CDCl3, 300 MHz) δ 7.2 - 7.4 (m, 10H), 5.69 (d, J = 3.8 Hz, 1H, H-1´), 4.92 (d, J = 3.4 
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Hz, 1H, H-1´´), 4.6 - 4.9 (m, 4H), 4.2 (m, 1H), 3.8 - 4.0 (m, 4H), 2.9 - 3.6 (m, 12H), 2.3 
(m, 1H), 1.3 - 1.6 (m, 5H), 1.24 (d, J = 6.2 Hz, 3H, H-6´´), 0.88 (t, J = 7.2 Hz, 3H); 
13
C 
NMR (CDCl3, 75 MHz) δ 138.8, 138.2, 128.7, 128.5 (2 carbons), 128.4 (2 carbons), 
128.2 (2 carbons), 128.0 (2 carbons), 127.7, 98.5, 98.2, 86.2, 83.6, 81.0, 79.8, 79.7, 75.9, 
75.5, 73.7, 73.5, 71.6, 71.3, 71.1, 68.8, 63.2, 59.4, 59.1, 51.3, 32.6, 32.4, 19.4, 17.8, 14.0; 
ESI/APCI calcd for C36H48N12O10Na
+
 ([M+Na]
+
) m/z 831.3509; measured m/z 831.3500. 
6-O-(2,3-Di-O-benzyl-6-deoxy-4-O-n-octyl-α-D-glucopyranosyl)-1,3,2´,6´-
tetraazidoneamine (19b).
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Please refer to the general procedure for glycosylation using 
thiophenyl donor, and hydrolysis. Compound 19b was obtained with 83% yield. 
6-O-(2,3-Di-O-benzyl-6-deoxy-4-O-n-dodecyl-α-D-glucopyranosyl)-1,3,2´,6´-
tetraazidoneamine (19c). Please refer to the general procedure for glycosylation and 
hydrolysis. Compound 19c was obtained with 74% yield.
 1
H NMR (CDCl3, 300 MHz) δ 
7.2 - 7.4 (m, 10H), 5.67 (d, J = 3.8 Hz, 1H, H-1´), 4.94 (d, J = 3.8 Hz, 1H, H-1´´), 4.6 - 
4.9 (m, 4H), 4.2 (m, 1H), 3.8 - 4.0 (m, 4H), 2.9 - 3.6 (m, 12H), 2.3 (m, 1H), 1.5 - 1.6 (m, 
2H), 1.33 (d, J = 6.2 Hz, 3H, H-6´´), 1.2 - 1.3 (m, 19H), 0.88 (t, J = 6.9 Hz, 3H); 
13
C 
NMR (CDCl3, 75 MHz) δ 138.8, 138.2, 128.6 (2 carbons), 128.5 (2 carbons), 128.1 (2 
carbons), 128.0 (2 carbons), 127.8, 127.7, 98.4, 98.2, 85.9, 83.7, 81.0, 79.8, 79.7, 75.9, 
75.7, 74.0, 73.5, 71.6, 71.3, 71.2, 68.7, 63.2, 59.4, 59.1, 51.3, 32.4, 32.0, 30.5, 29.8 (2 
carbons), 29.7 (2 carbons), 29.6, 29.5, 26.2, 22.8, 17.8, 14.2; ESI/APCI calcd for 
C44H64N12O10Na
+
 ([M+Na]
+
) m/z 943.4761; measured mze 943.4751. 
6-O-(6-Deoxy-4-O-n-butyl-α-D-glucopyranosyl)neamine (FG01). Please refer 
to the general procedure for the final synthesis of kanamycin B analogs. FG01 was 
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obtained with 45% yield as a chloride salt.
 1
H NMR (D2O, 300 MHz) δ 5.84 (d, J = 4.1 
Hz, 1H, H-1´), 4.84 (d, J = 3.1 Hz, 1H, H-1´´), 3.2 - 4.0 (m, 15H), 3.15 (dd, J = 6.9, 13.4 
Hz, 1H), 2.89 (t, J = 9.3 Hz, 1H), 2.4 (m, 1H), 1.7 - 1.8 (m, 1H), 1.4 (m, 2H), 1.2 (m, 
2H), 1.15 (d, J = 6.5 Hz, 3H, H-6´´), 0.73 (t, J = 7.2 Hz, 3H); 
13
C NMR (D2O, 75 MHz) δ 
101.6, 95.8, 83.6, 83.0, 77.4, 74.1, 73.2, 72.5, 71.9, 70.6, 69.2, 68.21, 68.17, 53.4, 49.9, 
48.3, 40.1, 31.4, 28.0, 18.6, 16.9, 13.1; ESI/APCI calcd for C22H45N4O10
+
 ([M+H]
+
) m/z 
525.3130; measured m/z 525.3140. 
6-O-(6-Deoxy-4-O-n-octyl-α-D-glucopyranosyl)neamine (FG08)103 Please refer 
to the general procedure for the final synthesis of kanamycin B analogs. FG08 was 
obtained with 20% yield as a chloride salt. 
6-O-(6-Deoxy-4-O-n-dodecyl-α-D-glucopyranosyl)neamine (FG02). Please 
refer to the general procedure for the final synthesis of kanamycin B analogs. FG02 was 
obtained with 34% yield as a chloride salt.
 1
H NMR (CDCl3, 300 MHz) δ 5.84 (s, 1H, H-
1´), 4.86 (s, 1H, H-1´´), 3.2 - 4.0 (m, 17H), 2.3 (m, 1H), 1.7 (m, 2H), 1.46 (d, J = 7.5 Hz, 
3H, H-6´), 1.1 (m, 19H), 0.7 (m, 3H); 
13
C NMR (CDCl3, 75 MHz) δ 101.6, 95.9, 83.8, 
83.6, 77.9, 74.1, 73.9, 72.7, 72.1, 70.8, 69.2, 68.5, 68.1, 53.6, 50.0, 48.4, 40.2, 31.7, 29.6, 
29.3 (4 carbons), 29.1 (2 carbons), 28.6, 25.5, 22.4, 17.1, 13.8; ESI/APCI calcd for 
C30H61N4O10
+
 ([M+H]
+
) m/z 637.4382; measured m/z 37.4395. 
Phenyl 2,3-di-O-benzyl-4-O-n-octyl-1-thio-β-D-glucopyranoside (20). To a 
solution of 17 (1.80 g, 3.98 mmol) in anhydrous CH2Cl2 were added TrCl (1.77 g, 6.36 
mmol), Et3N (1.12 mL, 7.95 mmol) and a catalytic amount of DMAP. The reaction 
mixture was stirred overnight at room temperature. When complete, the reaction was 
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quenched by addition of MeOH (5 mL). Then the mixture was washed with water, 
saturated aqueous NaHCO3, and brine, dried over Na2SO4 and concentrated. The 
tritylated crude product was then dissolved in anhydrous DMF, and octyl bromide (1.7 
mL, 9.79 mmol), NaH (0.39 g, 9.79 mmol) and a catalytic amount of TBAI were added. 
The reaction was stirred overnight. When complete, the reaction was quenched by 
addition of MeOH (5 mL) and was slowly poured into a mixture of ice and EtOAc. The 
aqueous layer was extracted with EtOAc. The combined organic layers were washed with 
water, saturated aqueous NaHCO3 and brine, and then dried over Na2SO4. After removal 
of the solvent, the obtained crude product was dissolved in 50 mL of a mixed solution of 
CH2Cl2:MeOH = 1:1 and p-toluenesulfonic acid monohydrate (0.61 g, 3.20 mmol) was 
added. The resulting mixture was stirred at room temperature overnight. When complete, 
the reaction mixture was quenched with Et3N (1.35 mL) and extracted with EtOAc. The 
organic layer was washed with 1N aqueous HCl, water, saturated aqueous NaHCO3, 
brine, and dried over Na2SO4. After removal of the solvent and purification with a 
gradient column chromatography (hexane:EtOAc = 100:0 to 40:60), 20 was obtained as a 
white solid (1.84 g, 3.26 mmol, 84%). 
1
H NMR (CDCl3, 300 MHz) δ 7.5 (m, 2H), 7.2 – 
7.4 (m, 13H), 4.88 (d, J = 10.3 Hz, 1H), 4.85 (s, 1H), 4.84 (s, 1H), 4.74 (d, J = 10.3 Hz, 
1H), 4.70 (d, J = 10.0 Hz, 1H), 3.9 (m, 1H), 3.5 – 3.8 (m, 4H), 3.43 (t, J = 9.6 Hz, 1H), 
3.3 (m, 2H), 1.94 (t, J = 6.9 Hz, 1H, OH), 1.5 (m, 2H), 1.2 (m, 10H), 0.87 (t, J = 6.9 Hz, 
3H); 
13
C NMR (CDCl3, 75 MHz) δ 138.5, 138.0, 133.5, 131.9 (2 carbons), 129.1 (2 
carbons), 128.5 (4 carbons), 128.3 (2 carbons), 128.0, 127.9, 127.82 (2 carbons), 127.75, 
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87.5, 86.5, 81.0, 79.5, 78.2, 75.9, 75.6, 73.6, 62.3, 31.9, 30.5, 29.6, 29.3, 26.2, 22.7, 14.2; 
ESI/APCI calcd for C34H44O5SNa ([M+Na]
+
) m/z 587.2802; measured m/z 587.2803. 
 Phenyl 2,3,6-tri-O-benzyl-4-O-n-octyl-1-thio-β-D-glucopyranoside (21). To a 
solution of 20 (1.15 g, 2.04 mmol) in DMF (40 mL) were added BnBr (0.49 mL, 4.07 
mmol) and a catalytic amount of TBAI. The mixture was then transferred in an ice-water 
bath and NaH (0.16 g, 4.07 mmol) was slowly added.  When TLC analysis performed the 
following day indicated completion, the reaction was quenched with MeOH (2 mL) and 
poured over ice. The mixture was extracted with EtOAc. The organic layer was washed 
with 1N aqueous HCl, saturated aqueous NaHCO3, water and brine, and then dried over 
Na2SO4. After removal of the solvent and purification with a gradient column 
chromatography (hexane:EtOAc = 100:0 to 50:50), 21 was obtained (1.26 g, 1.92 mmol, 
95%). 
1
H NMR (CDCl3, 300 MHz) δ 7.6 (m, 2H), 7.2 – 7.4 (m, 18H), 4.9 (m, 3H), 4.6 – 
4.8 (m, 4H), 3.7 – 3.9 (m, 3H), 3.4 – 3.7 (m, 5H), 1.5 (m, 2H), 1.3 (m, 10H), 0.91 (t, J = 
7.2 Hz, 3H);
 13
C NMR (CDCl3, 75 MHz) δ 138.6, 138.5, 138.2, 134.0, 132.0 (2 carbons), 
129.2 (2 carbons), 128.5 (4 carbons), 128.4 (2 carbons), 128.3 (2 carbons), 127.9 (2 
carbons), 127.8, 127.7 (3 carbons), 127.6, 127.5, 87.5, 86.8, 80.8, 79.4, 78.2, 75.9, 75.6, 
73.5, 73.4, 69.2, 32.0, 30.5, 29.6, 29.4, 26.3, 22.8, 14.3; ESI/APCI calcd for 
C41H50O5SNa ([M+Na]
+
) m/z 677.3271; measured m/z 677.3280. 
6-O-(2,3,6-Tri-O-benzyl-4-O-n-octyl-α-D-glucopyranosyl)-1,3,2´,6´-
tetraazidoneamine (22). Please refer to the general procedure for glycosylation and 
hydrolysis. Compound 22 was obtained with 47% yield.
 1
H NMR (CDCl3, 300 MHz) δ 
7.2 – 7.4 (m, 15H), 5.63 (d, J = 3.4 Hz, 1H, H-1´), 5.02 (d, J = 3.8 Hz, 1H, H-1´´), 4.92 
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(d, J = 11.0 Hz, 1H), 4.75 (d, J = 12.4 Hz, 1H), 4.72 (m, 2H), 4.64 (d, J = 12.0 Hz, 1H), 
4.51 (d, J = 12.4 Hz, 1H), 4.1 – 4.2 (m, 1H), 4.0 – 4.1 (m, 1H), 3.96 (d, J = 10.3 Hz, 1H), 
3.89 (d, J = 10.0 Hz, 1H), 3.2 – 3.8 (m, 18H), 2.31 (ddd, J = 13.1, 4.5, 4.1 Hz, 1H, H-
2eq), 1.51 (ddd, J = 13.0, 12.4, 12.4 Hz, 1H, H-2ax), 1.4 – 1.5 (m, 2H), 1.2 (m, 10H), 
0.88 (t, J = 6.9 Hz, 3H); 
13
C NMR (CDCl3, 75 MHz) δ 138.8, 138.1, 137.8, 128.55 (2 
carbons), 128.49 (2 carbons), 128.4 (2 carbons), 128.13 (2 carbons), 128.06 (2 carbons), 
128.0 (3 carbons), 127.9, 127.7, 98.6, 98.2, 86.3, 86.1, 81.4, 79.6, 78.0, 75.9, 75.7, 73.7, 
73.5 (2 carbons), 71.6 (2 carbons), 71.4, 71.1, 68.5, 62.9, 59.6, 59.2, 51.3, 32.4, 31.9, 
30.4, 29.6, 29.3, 26.2, 22.8, 14.2; ESI/APCI calcd for C47H62N12O11Na ([M+Na]
+
) m/z 
993.4553; measured m/z 993.4563. 
6-O-(4-O-n-Octyl-D-glucopyranosyl)neamine (FG03). Please refer to the 
general procedure for the final synthesis of kanamycin B analogs. FG03 was obtained 
with 42% yield as a chloride salt. 
1
H NMR (D2O, 300 MHz) (chloride salt) δ 5.81 (d, J = 
3.8 Hz, 1H, H-1´), 4.93 (d, J = 3.8 Hz, 1H, H-1´´), 3.3 - 4.0 (m, 17H), 3.1 – 3.2 (m, 2H), 
2.4 (m, 1H), 1.7 - 1.9 (m, 1H), 1.4 – 1.5 (m, 2H), 1.1 - 1.2 (m, 10H), 0.71 (t, J = 6.9 Hz, 
3H);
 13
C NMR (D2O, 100 MHz) (chloride salt) δ 101.7, 96.1, 83.8, 77.8, 77.6, 74.3, 73.7, 
72.9, 72.3, 71.8, 70.9, 69.4, 68.4, 60.4, 53.7, 49.9, 48.5, 40.3, 31.3, 29.4, 28.7, 28.6, 28.2, 
25.4, 22.2, 13.7; ESI/APCI calcd for C26H53N4O11
+ 
([M+H]
+
) m/z 597.3705; measured 
m/z 597.3708.   
 2,3-Di-O-benzyl-4-O-n-octyl-D-glucopyranose (25).  Compound 20 (0.90 g, 
1.59 mmol) was dissolved in a mixture of acetone (35 mL) and CH2Cl2 (10 mL). Distilled 
water (3.44 mL, 191.2 mmol) was added and the mixture was cooled down to 0 
o
C. N-
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bromosuccinimide (0.68 g, 3.82 mmol) was added and the reaction mixture was stirred 
overnight till room temperature. When complete, the solvent was evaporated and the 
residue was redissolved in EtOAc. The organic layer was washed with water and brine, 
and dried over Na2SO4. After removal of the solvent, purification by gradient column 
chromatography (Hexane:EtOAc = 100:0 to 0:100) afforded 25 (0.68 g, 1.44 mmol, 90%) 
as a mixture of α/β anomers in a 1/1 ratio. 1H NMR (α-anomer) (CDCl3, 300 MHz) δ 7.2 
– 7.4 (m, 10H), 5.16 (dd, J = 3.1, 3.1 Hz, 1H, H-1), 4.6 - 4.9 (m, 4H), 3.3 - 4.0 (m, 7H), 
3.17 (d, J = 2.4 Hz, 1H), 2.28 (dd, J = 7.2, 5.8 Hz, 1H), 1.94 (dd, J = 7.9, 4.8 Hz, 1H), 1.5 
(m, 2H), 1.2 (m, 10H), 0.87 (t , J = 6.9 Hz, 3H);
 13
C NMR (CDCl3, 75 MHz) δ 138.7, 
137.9, 128.6, 128.5 (3 carbons), 128.2, 128. 1 (2 carbons), 128.0, 127.9, 127.7, 91.4, 
83.1, 80.0, 78.0, 75.6, 75.0, 73.5, 71.2, 62.0, 31.9, 30.5, 29.6, 29.4, 26.2, 22.7, 14.2; 
ESI/APCI calcd for C28H40O6Na
 
([M+Na]
+
) m/z 495.2717; measured m/z 495.2720. 
4-O-n-Octyl-D-glucopyranose (23). Compound 25 (0.20 g, 0.42 mmol) was 
dissolved in a degassed mixture MeOH:H2O (1:1) and a catalytic amount of Pd(OH)2/C 
was added. The vial was then sealed and freed of air before H2 balloon was loaded. The 
reaction was stirred overnight under H2 atmosphere. The reaction was filtered through a 
short column packed with celite and eluted with water. Removal of the solvent afforded 
23 as a mixture of α/β anomers in a 10/9 ratio. (0.12 g, 0.41 mmol, 96%). 1H NMR (α-
anomer) (CD3OD, 300 MHz) δ 5.07 (d, J = 3.8 Hz, 1H, H-1), 3.0 – 4.0 (m, 8H), 1.5 – 1.6 
(m, 2H), 1.3 (m, 10 H), 0.88 (t, J = 6.9 Hz, 3H);
 13
C NMR (CD3OD, 100 MHz) δ 92.6, 
78.3, 76.0, 73.8, 72.7, 71.0, 61.1, 31.2, 30.2, 29.5, 29.3, 26.0, 22.5, 13.3; ESI/APCI calcd 
for C14H28O6Na
 
([M+Na]
+
) m/z 315.1778; measured m/z 315.1780. 
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Phenyl 2,3,4-tri-O-benzyl-1-thio-β-D-glucopyranoside (27).108 26 (2.00 g, 3.70 
mmol) was dissolved in 40 mL of a mixed solution of anhydrous Et2O:CH2Cl2 (1:1) and 
LiAlH4 (0.66 g, 17.4 mmol) was slowly added. The mixture was then gently heated. Then 
a solution of AlCl3 (1.97 g, 14.8 mmol) in anhydrous CH2Cl2 (20 mL) was added to the 
hot reaction mixture over a 1 h period. The combined solutions were then refluxed at 40 
o
C. Two hours later, the reaction was complete as confirmed by TLC analysis. The 
reaction was quenched by transferring it to flask containing ice and EtOAc. The organic 
layer was washed with 1 N HCl, water, saturated aqueous NaHCO3, and brine, and dried 
over Na2SO4. Removal of the solvent gave a crude product that was recrystallized in 
diethyl ether and hexane to give 27 (1.34g, 2.47 mmol, 67%). 
Phenyl 2,3,4-tri-O-benzyl-6-O-n-hexyl-1-thio-β-D-glucopyranoside (28a). 
Please refer to the general procedure for O-alkylation of sugars. Compound 28a was 
obtained with 99% yield. 
1
H NMR (CDCl3, 300 MHz) δ 7.6 – 7.7 (m, 2H), 7.2 – 7.5 (m, 
18H), 4.9 – 5.0 (m, 4H), 4.77 (d, J = 10.0 Hz, 1H), 4.70 (d, J = 10.0 Hz, 2H), 3.6 – 3.8 
(m, 4H), 3.4 – 3.6 (m, 4H), 1.6 (m, 2H), 1.2 – 1.5 (m, 6H), 0.93 (t, J = 7.1 Hz, 3H); 13C 
NMR (CDCl3, 75 MHz) δ 138.6, 138.3, 138.2, 134.1, 132.0 (2 carbons), 129.0 (2 
carbons), 128.60 (5 carbons), 128.57 (2 carbons), 128.4 (2 carbons), 128.03 (2 carbons), 
127.97 (3 carbons), 127.9, 127.5, 87.6, 86.9, 81.0, 79.3, 78.0, 76.0, 75.6, 75.2, 71.9, 69.7, 
31.9, 30.0, 26.0, 22.3, 14.3; ESI/APCI calcd for C39H46O5S Na ([M+Na]
+
) m/z 649.2958, 
measured m/z 649.2971. 
Phenyl 2,3,4-tri-O-benzyl-6-O-n-octyl-1-thio-β-D-glucopyranoside (28b). 
Please refer to the general procedure for O-alkylation of sugars. Compound 28b was 
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obtained with 97% yield.
 1
H NMR (CDCl3, 300 MHz) δ 7.6 – 7.7 (m, 2H), 7.2 – 7.5 (m, 
18H), 4.9 – 5.0 (m, 4H), 4.79 (d, J = 10.3 Hz, 1H), 4.71 (d, J = 10.0 Hz, 2H), 3.7 – 3.8 
(m, 4H), 3.4 – 3.6 (m, 4H), 1.6 (m, 2H), 1.2 – 1.5 (m, 10H), 0.94 (t, J = 6.9 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 138.6, 138.4, 138.2, 134.2, 132.0 (2 carbons), 129.0 (2 
carbons), 128.63 (5 carbons), 128.64 (2 carbons), 128.4 (2 carbons), 128.1 (2 carbons), 
128.0 (3 carbons), 127.9, 127.5, 87.7, 86.9, 81.0, 79.4, 78.0, 76.0, 75.6, 75.2, 71.9, 69.8, 
32.1, 30.1, 29.7, 29.5, 26.4, 22.9, 14.3; ESI/APCI calcd for C41H50O5SNa ([M+Na]
+
) m/z 
677.3271, measured m/z 677.3280. 
6-O-(2,3,4-Tri-O-benzyl-6-O-n-hexyl-α-D-glucopyranosyl)-1,3,2´,6´-
tetraazidoneamine (29a). Please refer to the general procedure for glycosylation and 
hydrolysis. Compound 29a was obtained with 40% yield. 
1
H NMR (CDCl3, 300 MHz) δ 
7.2 - 7.4 (m, 15H), 5.69 (d, J = 3.8 Hz, 1H, H-1'), 5.05 (d, J = 3.8 Hz, 1H, H-1''), 4.97 (d, 
J = 11.0 Hz, 1H), 4.88 (d, J = 10.7 Hz, 1H), 4.82 (d, J = 11.0 Hz, 1H), 4.75 (s, 1H), 4.74 
(s, 1H), 4.59 (d, J = 10.7 Hz, 1H), 4.48 (d, J = 2.4 Hz, 1H), 4.1 – 4.2 (m, 1H), 3.9 – 4.1 
(m, 3H), 3.1 – 3.7 (m, 15H), 2.97 (d, J = 3.4 Hz, 1H), 2.92 (d, J = 4.1 Hz, 1H), 2.32 (ddd, 
J = 13.1, 4.5, 4.1 Hz, 1H, H-2eq), 1.6 (m, 2H), 1.50 (ddd, J = 13.1, 12.7, 12.7 Hz, 1H, H-
2ax), 1.2 – 1.4 (m, 6H), 0.88 (t, J = 6.9 Hz, 3H); 13C NMR (CDCl3, 75 MHz) δ 138.8, 
138.16, 138.07, 128.61 (2 carbons), 128.58 (2 carbons), 128.51 (2 carbons), 128.16 (2 
carbons), 128.10 (4 carbons), 128.04 (2 carbons), 127.8, 98.6, 98.2, 85.9, 81.5, 79.7, 79.6, 
75.8 (2 carbons), 75.4, 73.5, 71.9 (2 carbons), 71.7, 71.6, 71.4, 71.1, 69.1, 63.0, 59.6, 
59.2, 51.3, 32.4, 31.7, 29.4, 25.8, 22.7, 14.2 ; ESI/APCI calcd for C47H62N12O11Na 
([M+Na]
+
) m/z 965.4240; measured m/z 965.4255. 
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6-O-(2,3,4-Tri-O-benzyl-6-O-n-octyl-α-D-glucopyranosyl)-1,3,2´,6´-
tetraazidoneamine (29b). Please refer to the general procedure for glycosylation and 
hydrolysis. Compound 29b was obtained with 38% yield. 
1
H NMR (CDCl3, 300 MHz) δ 
7.2 - 7.4 (m, 15H), 5.69 (d, J = 3.8 Hz, 1H, H-1'), 5.05 (d, J = 3.8 Hz, 1H, H-1''), 4.97 (d, 
J = 11.0 Hz, 1H), 4.88 (d, J = 10.7 Hz, 1H), 4.82 (d, J = 11.0 Hz, 1H), 4.75 (s, 1H), 4.74 
(s, 1H), 4.59 (d, J = 10.7 Hz, 1H), 4.48 (d, J = 2.4 Hz, 1H), 4.1 – 4.2 (m, 1H), 3.9 – 4.1 
(m, 3H), 3.1 – 3.7 (m, 15H), 2.97 (d, J = 3.4 Hz, 1H), 2.92 (d, J = 4.1 Hz, 1H), 2.32 (ddd, 
J = 13.1, 4.5, 4.1 Hz, 1H, H-2eq), 1.6 (m, 2H), 1.50 (ddd, J = 13.1, 12.7, 12.7 Hz, 1H, H-
2ax), 1.2 – 1.4 (m, 6H), 0.88 (t, J = 6.9 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 138.9, 
138.3, 138.2, 128.7 (4 carbons), 128.6 (2 carbons), 128.23 (6 carbons), 128.22 (2 
carbons), 127.9, 98.7, 98.3, 85.8, 81.6, 79.8 (2 carbons), 77.7, 75.9 (2 carbons), 75.5, 
73.6, 72.0, 71.8, 71.7, 71.6, 71.3, 69.2, 63.2, 59.7, 59.3, 51.4, 32.5, 32.1, 29.7, 29.6, 29.5, 
26.3, 22.9, 14.3 ; ESI/APCI calcd for C47H62N12O11Na ([M+Na]
+
) m/z 993.4611; 
measured m/z 993.4578.  
6-O-(6-O-n-Hexyl-D-glucopyranosyl)neamine (FG05). Please refer to the 
general procedure for the final synthesis of kanamycin B analogs. FG05 was obtained 
with 86% yield as a chloride salt. 
1
H NMR (D2O, 300 MHz) (chloride salt) δ 5.85 (d, J = 
4.1 Hz, 1H, H-1´), 4.89 (d, J = 3.5 Hz, 1H, H-1´´), 3.2 - 4.0 (m, 18H), 3.1 (m, 1H), 2.4 
(m, 1H), 1.8 (m, 1H), 1.3 – 1.5 (m, 2H), 1.0 - 1.2 (m, 6H), 0.69 (t, J = 6.9 Hz, 3H); 13C 
NMR (D2O, 100 MHz) (chloride salt) δ 101.9, 95.5, 83.8, 77.0, 74.3, 72.9, 72.11, 72.07, 
71.7, 70.8, 69.4, 69.3, 68.8, 68.4, 53.6, 49.9, 48.4, 40.4, 31.1, 28.6, 28.1, 25.0, 22.1, 13.6; 
ESI/APCI calcd for C24H49N4O11
 
([M+H]
+
) m/z 569.3392; measured m/z 569.3408.   
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6-O-(6-O-n-Octyl-D-glucopyranosyl)neamine (FG06). Please refer to the 
general procedure for the final synthesis of kanamycin B analogs. FG06 was obtained 
with 82% yield as a chloride salt. 
1
H NMR (D2O, 300 MHz) (chloride salt) δ 5.92 (d, J = 
4.1 Hz, 1H, H-1´), 4.95 (d, J = 3.8 Hz, 1H, H-1´´), 3.3 - 4.0 (m, 18H), 3.2 (m, 1H), 2.4 – 
2.5 (m, 1H), 1.9 (m, 1H), 1.4 – 1.5 (m, 2H), 1.1 - 1.2 (m, 10H), 0.74 (t, J = 7.2 Hz, 3H); 
13
C NMR (D2O, 100 MHz) (chloride salt) δ 102.0, 95.6, 83.8, 76.9, 74.3, 72.9, 72.2, 72.1, 
71.8, 70.9, 69.5, 69.3, 68.8, 68.4, 53.7, 49.9, 48.6, 40.4, 31.3, 28.8, 28.7, 28.6, 28.0, 25.4, 
22.2, 13.7; ESI/APCI calcd for C26H53N4O11
 
([M+H]
+
) m/z 597.3705; measured m/z 
597.3708.   
1,2:5,6-Di-O-isopropylidene-3-O-n-octyl-α-D-glucopyranose (30).109 Please 
refer to the general procedure for O-alkylation of sugars. Compound 30 was obtained 
with 99% yield. 
1,2,4,6-Tetra-O-acetyl-3-O-n-octyl-D-glucopyranose (31). Please refer to the 
synthesis of 6. Compound 31 was obtained with 87% yield as a mixture of α/β anomers in 
the ratio 1/2. 
1
H NMR (CDCl3, 300 MHz) ( and  anomers) δ 6.27 (d, J = 3. 8 Hz,1H, 
H-1), 5.62 (d, J = 8.3 Hz, 1H, H-1), 4.9 – 5.5.1 (m, 4H), 3.9 – 4.2 (m, 4H), 3.4 – 3.8 
(m, 8H), 2.0 – 2.1 (m, 24H), 1.1 – 1.3 (m, 24H), 0.86 (t, J = 6.9 Hz, 6H). 
Phenyl 2,4,6-tri-O-acetyl-3-O-n-octyl-1-thio-β-D-glucopyranoside (32). A 
solution of 31 (4.04 g, 8.77 mmol) and thiophenol (3.4 mL, 33.3 mmol) in anhydrous 
CH2Cl2 (50 mL) was cooled down to 0 
o
C and BF3-OEt2 was slowly added. The reaction 
was stirred for 2 days till completion. Solid NaHCO3, Na2SO4 and some few drops of 
water were then added and the mixture was stirred for 1 h. The solution was then filtered 
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through a Fritz funnel and the collected solids were washed with EtOAc. After removal 
of the solvents, purification by gradient column chromatography afforded 32 (2.91 g, 
5.70 mmol, 65%). 
1
H NMR (CDCl3, 300 MHz) δ 7.4 (m, 2H), 7.1 – 7.2 (m, 3H), 4.89 
(dd, J = 9.6, 9.6 Hz, 1H, H-2), 4.88 (dd, J = 9.6, 9.6 Hz, 1H, H-4), 4.56 (d, J = 10.3 Hz, 
1H, H-1), 3.9 – 4.1 (m, 3H), 3.5 – 3.6 (m, 1H), 3.4 – 3.5 (m, 2H), 2.03 (s, 3H), 2.00 (s, 
3H), 1.95 (s, 3H), 1.3 – 1.4 (m, 2H), 1.1 – 1.2 (m, 10H), 0.77 (t, J = 6.9 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 170.6, 169.4, 169.2, 132.9, 132.5 (2 carbons), 129.0 (2 
carbons), 128.1, 86.2, 81.9, 76.1, 72.9, 71.5, 69.8, 62.7, 31.9, 30.4, 29.5, 29.4, 26.1, 22.7, 
21.1, 20.9, 20.8, 14.2 ; ESI/APCI calcd for C26H38O8SNa ([M+Na]
+
) m/z 533.2180; 
measured m/z 533.2187.  
Phenyl 2,3,6-tri-O-benzyl-4-O-n-octyl-1-thio-β-D-glucopyranoside (33). To a 
solution of 32 (2.91 g, 5.70 mmol) in anhydrous MeOH (40 mL), 0.5 mL of a 1M 
solution of NaOMe in MeOH was added and the mixture was stirred at room temperature 
for 1 h. When complete, the reaction was quenched by adding amberlite IR 120 H
+ 
resin 
to the mixture, followed by filtration through celite and concentration of the filtrate. The 
obtained crude product was dissolved in DMF (40 mL), and BnBr (10.0 mL, 84.0 mmol) 
and a catalytic amount of TBAI were added. The mixture was then transferred in an ice-
water bath and NaH (3.36 g, 84.0 mmol) was slowly added.  When TLC analysis 
performed the following day indicated completion, the reaction was quenched with 
MeOH (5 mL) and poured over ice. The mixture was diluted with EtOAc, extracted with 
1N aqueous HCl, saturated aqueous NaHCO3, water and brine, and dried over Na2SO4. 
After removal of the solvents, purification by gradient column chromatography 
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(Hexane:EtOAc = 100:0 to 50:50) gave 33 (2.00 g, 3.05 mmol, 44%). 
1
H NMR (CDCl3, 
300 MHz) δ 7.2 – 7.8 (m, 20H), 5.0 (m, 2H), 4.86 (d, J = 10.3 Hz, 1H), 4.6 – 4.8 (m, 4H), 
3.8 – 4.0 (m, 4H), 3.5 – 3.7 (m, 4H), 1.7 – 1.8 (m, 2H), 1.3 - 1.5 (m, 10H), 1.01 (t, J = 6.9 
Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ 138.7, 138.65, 138.55, 134.3, 132.3 (2 carbons), 
129.2 (2 carbons), 128.75 (4 carbons),128.67 (2 carbons), 128.5 (2 carbons), 128.3 (2 
carbons), 128.1 (2 carbons), 128.0 (2 carbons), 127.9, 127.7, 87.7, 87.1, 81.2, 79.4, 78.1, 
75.7, 75.3, 74.4, 73.7, 69.4, 32.2, 31.0, 29.9, 29.6, 26.7, 23.0, 14.5 ; ESI/APCI calcd for 
C41H50O5SNa ([M+Na]
+
) m/z 677.3271; measured m/z 677.3270. 
6-O-(2,4,6-Tri-O-benzyl-3-O-n-octyl-α-D-glucopyranosyl)-1,3,2´,6´-
tetraazidoneamine (34). Please refer to the general procedure for glycosylation and 
hydrolysis. Compound 34 was obtained with 59% yield.
 1
H NMR (CDCl3, 300 MHz) δ 
7.1 – 7.5 (m, 15H), 5.60 (d, J = 3.8 Hz, 1H, H-1´), 5.02 (d, J = 3.8 Hz, 1H, H-1´´), 4.83 
(d, J = 10.7 Hz, 1H), 4.76 (d, J = 12.0 Hz, 1H), 4.70 (d, J = 11.7 Hz, 1H), 4.61 (d, J = 
12.4 Hz, 1H), 4.54 (s, 1H), 4.53 (s, 1H), 4.49 (d, J = 12.4 Hz, 1H), 4.45 d, J = 10.7 Hz, 
1H), 4.0 – 4.1 (m, 2H), 3.0 – 4.0 (m, 18H), 2.30 (ddd, J  =13.1, 4.5, 4.1 Hz, 1H, H-2eq), 
1.6 – 1.7 (m, 2H), 1.49 (ddd, J = 12.7, 12.7, 12.7 Hz, 1H, H-2ax), 1.2 -1.4 (m, 10H), 0.88 
(t, J = 6.9 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ 138.4, 138.1, 137.9, 128.7 (6 
carbons), 128.32 (2 carbons), 128.25 (2 carbons), 128.1 (4 carbons), 128.0, 98.7, 98.4, 
85.8, 81.5, 79.9, 79.6, 77.8, 75.9, 75.4, 74.0, 73.6 (2 carbons), 71.7, 71.5 (2 carbons), 
71.3, 68.5, 63.0, 59.7, 59.3, 51.4, 32.5,32.1,30.9, 29.8, 29.5, 26.5, 22.9, 14.3 ; ESI/APCI 
calcd for C47H62N12O11Na ([M+Na]
+
) m/z 993.4553; measured m/z 993.4564. 
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6-O-(3-O-n-Octyl-D-glucopyranosyl)neamine (FG07). Please refer to the 
general procedure for the final synthesis of kanamycin B analogs. FG07 was obtained 
with 42% yield as a chloride salt. 
1
H NMR (D2O, 300 MHz) (chloride salt) δ 5.81 (d, J = 
4.1 Hz, 1H, H-1´), 4.93 (d, J = 4.0 Hz, 1H, H-1´´), 3.3 - 4.0 (m, 18H), 3.16 (dd, J = 13.7, 
6.9 Hz, 1H), 2.42 (ddd, J = 12.4, 4.1, 4.1 Hz, 1H, H-2eq), 1.87 (ddd, J = 12.7, 12.4, 12.4 
Hz, 1H, H-2ax), 1.4 – 1.5 (m, 2H), 1.0 - 1.3 (m, 10H), 0.71 (t, J = 6.9 Hz, 3H); 13C NMR 
(D2O, 100 MHz) (chloride salt) δ 101.8, 96.2, 83.8, 81.3, 77.7, 74.2, 73.4, 73.2, 71.3, 
70.8, 69.4, 68.9, 68.4, 60.5, 53.6, 49.9, 48.4, 40.3, 31.3, 29.5, 28.7, 28.6, 28.1, 25.3, 22.2, 
13.6; ESI/APCI calcd for C26H53N4O11
 
([M+H]
+
) m/z 597.3705; measured m/z 597.3720.   
Methyl 3-O-benzyl-4,6-O-benzylidene-2-O-n-octyl-α-D-glucopyranoside (36). 
Please refer to the general procedure for O-alkylation of sugars. Compound 36 was 
obtained with 90% yield.
 1
H NMR (CDCl3, 300 MHz) δ 7.5 (m, 2H), 7.2 – 7.4 (m, 8H), 
5.58 (s, 1H), 4.89 (d , J = 11.3 Hz, 1H), 4.84 (d, J = 3.8 Hz, 1H, H-1), 4.82 (d, J = 11.3 
Hz, 1H), 4.30 (dd, J = 9.6, 4.1 Hz, 1H, H-2), 3.98 (dd, J = 9.3, 8.9 Hz, 1H, H-4), 3.6 – 3.9 
(m, 6H), 3.46 (s, 3H), 1.6 – 1.7 (m, 2H), 1.2 – 1.4 (m, 10H), 0.90 (t, J = 6.9 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 139.0, 137.7, 129.1, 128.5 (2 carbons), 128.4 (2 carbons), 
128.2 (2 carbons), 127.7, 126.3 (2 carbons), 101.5, 99.2, 82.2, 80.7, 78.6, 75.5, 72.4, 
69.3, 62.6, 55.2, 32.1, 30.3, 29.7, 29.5, 26.2, 22.9, 14.4 ; ESI/APCI calcd for C29H40O6Na 
([M+Na]
+
) m/z 507.2717; measured m/z 507.2723. 
1,3,4,6-Tetra-O-acetyl-2-O-n-octyl-D-glucopyranose (37). Please refer to the 
synthesis of 6. Compound 37 was obtained with 76% yield as a mixture of α/β anomers in 
a 6/1 ratio. 
1
H NMR (α-anomer) (CDCl3, 300 MHz) δ 6.25 (d, J = 3.8 Hz, 1H, H-1), 5.21 
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(dd, J = 10.0, 9.6 Hz, 1H, H-4), 4.94 (dd, J = 10.3, 9.6 Hz, 1H, H-3), 4.17 (dd, J = 13.0, 
4.1 Hz, 1H), 3.9 – 4.0 (m, 2H), 3.4 – 3.6 (m, 2H), 3.3 (m, 1H), 2.05 (s, 3H), 1.95 (s, 3H), 
1.92 (s, 3H), 1.91 (s, 3H), 1.3 – 1.4 (m, 2H), 1.1 (m, 10H), 0.75 (t, J = 6.9 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 170.5, 170.1, 169.7, 169.0, 89.3, 76.7, 71.6 (2 carbons), 69.8, 
68.1, 61.7, 31.9, 29.8, 29.3 (2 carbons), 25.9, 22.7, 21.0, 20.8, 20.72, 20.66, 14.1 ; 
ESI/APCI calcd for C22H36O10Na ([M+Na]
+
) m/z 483.2201; measured m/z 483.2192. 
Phenyl 3,4,6-tri-O-acetyl-2-O-n-octyl-1-thio-D-glucopyranoside (38). Please 
refer to the synthesis of 32. Compound 38 was obtained with 56% yield as a mixture of 
α/β anomers in a 3/1 ratio.1H NMR (-anomer) (CDCl3, 300 MHz) δ 7.5 (m, 2H), 7.3 (m, 
3H), 5.77 (d, J = 5.5 Hz, 1H, H-1), 5.30 (dd, J = 9.6, 9.6 Hz, 1H, H-4), 5.01 (dd, J = 10.3, 
9.3 Hz, 1H, H-3), 4.54 (ddd, J = 10.3, 5.2, 2.1 Hz, 1H, H-5), 4.29 (dd, J = 12.0, 5.2 Hz, 
1H, H-6), 3.99 (dd, J = 12.4, 2.1 Hz, 1H, H-6´), 3.6 – 3.8 (m, 2H), 3.3 – 3.5 (m, 1H), 2.04 
(s, 3H), 2.03 (s, 3H), 2.01 (s, 3H), 1.5 (m, 2H), 1.2 – 1.4 (m, 10H), 0.87 (t, J = 6.9 Hz, 
3H). 
Phenyl 3,4,6-tri-O-benzyl-2-O-n-octyl-1-thio-α-D-glucopyranoside (39). Please 
refer to the synthesis of 33. Compound 39 was obtained with 95% yield. 
1
H NMR 
(CDCl3, 300 MHz) δ 7.5 – 7.7 (m, 2H), 7.2 -7.5 (m, 18H), 5.86 (d, J = 4.8 Hz, 1H, H-1), 
5.10 (d, J = 11.0 Hz, 1H), 4.95 (d, J = 10.7 Hz, 1H), 4.87 (d, J = 10.7 Hz, 1H), 4.68 (d, J 
= 11.7 Hz, 1H), 4.59 (d, J = 11.0 Hz, 1H), 4.50 (d, J = 12.1 Hz, 1H), 3.5 – 4.0 (m, 8H), 
1.6 – 1.8 (m, 2H), 1.3 – 1.5 (m, 10H), 0.95 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 100 
MHz) δ 139.2, 138.6, 138.3, 135.1, 132.0, 131.8 (2 carbons), 129.2 (2 carbons), 128.7 (5 
carbons), 128.3 (3 carbons), 128.2 (3 carbons), 128.0 (2 carbons), 127.9, 127.3, 87.2, 
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82.8, 81.0, 77.2, 76.0, 75.4, 73.7, 71.5, 70.7, 68.9, 32.2, 30.4, 29.8, 29.6, 26.5, 23.0, 
14.5 ; ESI/APCI calcd for C41H50O5NaS ([M+Na]
+
) m/z 677.3271; measured m/z 
677.3277. 
6-O-(3,4,6-Tri-O-benzyl-2-O-n-octyl-α-D-glucopyranosyl)-1,3,2´,6´-
tetraazidoneamine (40). Please refer to the general procedure for glycosylation and 
hydrolysis. Compound 40 was obtained with 59% yield. 
1
H NMR (CDCl3, 300 MHz) δ 
7.1 – 7.5 (m, 15H), 5.60 (d, J = 3.8 Hz, 1H, H-1´), 5.02 (d, J = 3.8 Hz, 1H, H-1´´), 4.83 
(d, J = 10.7 Hz, 1H), 4.76 (d, J = 12.0 Hz, 1H), 4.70 (d, J = 11.7 Hz, 1H), 4.61 (d, J = 
12.4 Hz, 1H), 4.54 (s, 1H), 4.53 (s, 1H), 4.49 (d, J = 12.4 Hz, 1H), 4.45 d, J = 10.7 Hz, 
1H), 4.0 – 4.1 (m, 2H), 3.0 – 4.0 (m, 18H), 2.30 (ddd, J  =13.1, 4.5, 4.1 Hz, 1H, H-2eq), 
1.6 – 1.7 (m, 2H), 1.49 (ddd, J = 12.7, 12.7, 12.7 Hz, 1H, H-2ax), 1.2 -1.4 (m, 10H), 0.88 
(t, J = 6.9 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ 138.4, 138.1, 137.9, 128.7 (6 
carbons), 128.32 (2 carbons), 128.25 (2 carbons), 128.1 (4 carbons), 128.0, 98.7, 98.4, 
85.8, 81.5, 79.9, 79.6, 77.8, 75.9, 75.4, 74.0, 73.6 (2 carbons), 71.7, 71.5 (2 carbons), 
71.3, 68.5, 63.0, 59.7, 59.3, 51.4, 32.5,32.1,30.9, 29.8, 29.5, 26.5, 22.9, 14.3 ; ESI/APCI 
calcd for C47H62N12O11Na ([M+Na]
+
) m/z 993.4553; measured m/z 993.4564. 
6-O-(2-O-n-Octyl-D-glucopyranosyl)neamine (FG09). Please refer to the 
general procedure for the final synthesis of kanamycin B analogs. FG09 was obtained 
with 52% yield as a chloride salt. 
1
H NMR (D2O, 300 MHz) (chloride salt) δ 5.81 (d, J = 
3.8 Hz, 1H, H-1´), 5.06 (d, J = 3.4 Hz, 1H, H-1´´), 3.0 - 4.0 (m, 19H), 2.4 (m, 1H), 1.4 – 
1.5 (m, 3H), 1.1 - 1.2 (m, 10H), 0.72 (t, J = 6.5 Hz, 3H); 
13
C NMR (D2O, 100 MHz) 
(chloride salt) δ 100.3, 96.4, 83.9, 80.1, 78.0, 74.4, 73.3, 73.2, 72.7, 70.8, 69.5, 69.4, 
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68.4, 60.7, 53.7, 49.8, 48.4, 40.3, 31.3, 29.3, 28.7, 28.5, 28.0, 25.1, 22.2, 13.6; ESI/APCI 
calcd for C26H53N4O11 ([M+H]
+
) m/z 597.3705; measured m/z 597.3701. 
3´,4´-Di-O-benzyl-1,3,2´,6´-Tetraazidoneamine (41)
98
. To a solution of 14 (3.60 
g, 7.11 mmol) in DMF (40 mL) were added BnBr (3.40 mL, 28.5 mmol) and a catalytic 
amount of TBAI. The mixture was then transferred in an ice-water bath and NaH (1.14 g, 
28.5 mmol) was slowly added.  When TLC analysis performed the following day 
indicated completion, the reaction was quenched with MeOH (2 mL) and poured over 
ice. The mixture was extracted with EtOAc. The organic layer was washed with 1N 
aqueous HCl, saturated aqueous NaHCO3, water and brine, and dried over Na2SO4. After 
removal of the solvent, a brownish crude product was obtained, to which 80 mL of mixed 
solution of dioxane: H2O = 1:1 was added, followed by 35 mL glacial acetic acid. The 
resulting mixture was refluxed at 60~65 
o
C overnight. When complete, the reaction 
mixture was quenched with saturated aqueous NaHCO3 and extracted with EtOAc. The 
organic layer was washed with 1N aqueous HCl, water, saturated aqueous NaHCO3, 
brine, and dried over Na2SO4. After removal of the solvent followed by purification with 
a gradient column chromatography (pure hexane to hexane: EtOAc = 40:60), 41 was 
obtained (2.03 g, 6.62 mmol, 42%). 
6-O-(2,3,4,6-Tetra-O-benzyl-α-D-glucopyranosyl)-3´,4´-O-dibenzyl-1,3,2´,6´-
tetraazidoneamine (43a). A solution of 41 (0.20 g, 0.33 mmol), 42a (0.25 g, 0.40 
mmol), and activated powder 4 Å molecular sieve was stirred at room temperature for 2 h 
in 12 mL of a mixed anhydrous solution Et2O:CH2Cl2 = 3:1. The mixture was cooled to -
70 
o
C and N-iodosuccinimide (0.09 g, 0.40 mmol) was quickly added. After the 
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temperature has warmed up to -40 
o
C, trifluoromethanesulfonic acid (0.05 mL) was 
added. The solution was stirred at low temperature till the complete consumption of the 
glycosyl donor. The reaction mixture was quenched by addition of solid NaHCO3, 
Na2S2O3 and Na2SO4. After being stirred for 15 minutes, the reaction mixture was filtered 
through celite. The residue was washed thoroughly with EtOAc. After removal of the 
solvents, the crude product was purified with gradient column chromatography 
(Hexane:EtOAc = 100:0 to 50:50) to afford 43a. Because it was mixed with inseparable 
impurities, it was used as so in the next step. 
6-O-(3-Azido-3-deoxy-2,4,6-tri-O-benzyl-α-D-glucopyranosyl)-3´,4´-O-
dibenzyl-1,3,2´,6´-tetraazidoneamine (43b). Please refer to the synthesis of 43a. 
Compound 43b was also obtained mixed with inseparable impurities and was then used 
as so in the next step. 
6-O-(2,3,4,6-Tetra-O-benzyl-α-D-glucopyranosyl)-3´,4´-O-dibenzyl-5-O-n-
octyl-1,3,2´,6´-tetraazidoneamine (44a). Please refer to the general procedure for O-
alkylation of sugars. Compound 44a was obtained with 57% yield. 
1
H NMR (CDCl3, 300 
MHz) δ 7.2 -7.5 (m, 30H), 5.72 (d, J = 3.4 Hz, 1H, H-1´), 5.62 (d, J = 3.8 Hz, 1H, H-1´´), 
4.8 – 5.0 (m, 8H), 4.67 (d, J = 11.3 Hz, 1H), 4.65 (d, J = 12.0 Hz, 1H), 4.53 (d, J = 11.3 
Hz, 1H), 4.47 (d, J = 12.0 Hz, 1H), 4.32 (d, J = 9.6 Hz, 1H), 4.15 (d, J = 10.0 Hz, 1H), 
4.04 (dd, J = 10.3, 8.9 Hz, 1H), 3.9 – 4.0 (m, 1H), 3.3 – 3.8 (m, 15H), 2.4 (m, 1H), 1.5 – 
1.7 (m, 3H), 1.0 - 1.4 (m, 10H), 0.86 (t, J = 7.2 Hz, 3H); 
13
C NMR (CDCl3, 75 MHz) δ 
138.8, 138.7, 138.1 (2 carbons), 137.83, 137.77, 128.64 (3 carbons), 128.57 (3 carbons), 
128.49 (4 carbons), 128.25 (3 carbons), 128.20 (4 carbons), 128.1 (3 carbons), 128. 0 (3 
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carbons), 127.9 (2 carbons), 127.8, 127.7, 127.6 (2 carbons), 127.5, 97.5, 96.0, 83.3, 82.1, 
80.2, 79.5, 78.8, 77.7, 77.5, 76.1, 75.8, 75.7, 75.5, 75.2, 75.1, 73.5, 73.4, 71.1, 70.2, 68.5, 
63.5, 60.6, 60.5, 59.3, 32.1, 31.9, 30.2, 29.7, 29.6, 26.1, 22.8, 14.2; ESI/APCI calcd for 
C68H80N12O11Na ([M+Na]
+
) m/z 1263.5962; measured m/z 1263.5961. 
6-O-(3-Azido-3-deoxy-2,4,6-tri-O-benzyl-α-D-glucopyranosyl)-3´,4´-O-
dibenzyl-5-O-n-octyl-1,3,2´,6´-tetraazidoneamine (44b). Please refer to the general 
procedure for O-alkylation of sugars. Compound 44b was obtained with 52% yield. 
1
H 
NMR (CDCl3, 300 MHz) δ 7.2 -7.5 (m, 25H), 5.70 (d, J = 3.5 Hz, 1H, H-1´), 5.58 (d, J = 
3.8 Hz, 1H, H-1´´), 4.92 (d, J = 11.3 Hz, 1H), 4.91 (s, 2H), 4.82 (d, J = 12.0 Hz, 1H), 
4.80 (d, J = 10.6 Hz, 1H), 4.76 (d, J = 12.0 Hz, 1H), 4.65 (d, J = 11.3 Hz, 1H), 4.64 (d, J 
= 12.0 Hz, 1H), 4.47 (d, J = 12.0 Hz, 1H), 4.3 (m, 1H), 4.11 (d, J = 10.0 Hz, 1H), 4.02 
(dd, J = 10.3, 8.9 Hz, 1H), 3.3 – 3.9 (m, 17H), 2.3 – 2.4 (m, 1H), 1.4 – 1.7 (m, 3H), 1.0 – 
1.3 (m, 10H), 0.88 (t, J = 7.2 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ 138.2, 138.0, 
137.9, 137.8, 137.6, 128.8 (5 carbons), 128.7 (2 carbons), 128.43 (2 carbons), 128.40 (2 
carbons), 128.3 (5 carbons), 128.2 (2 carbons), 128.04 (4 carbons), 128.00 (2 carbons), 
127.9, 97.6, 95.2, 83.3, 80.3, 78.9, 77.5, 76.5 (2 carbons), 76.3, 75.8, 75.5, 75.3, 75.1, 
73.8, 73.1, 71.2, 69.9, 68.3, 65.8, 63.6, 60.5, 59.3, 51.2, 32.1, 32.0, 30.3, 29.7, 29.6, 26.0, 
22.9, 14.3; ESI/APCI calcd for C61H73N15O10Na ([M+Na]
+
) m/z 1198.5557; measured m/z 
1198.5527. 
6-O-(α-D-Glucopyranosyl)-5-O-n-octylneamine (FG10). Please refer to the 
general procedure for the final synthesis of kanamycin B analogs. FG10 was obtained 
with 81% yield as a chloride salt. 
1
H NMR (D2O, 300 MHz) (chloride salt) δ 5.59 (d, J = 
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3.8 Hz, 1H, H-1´), 5.01 (d, J = 3.4 Hz, 1H, H-1´´), 3.0 - 4.0 (m, 19H), 2.4 (m, 1H), 1.9 
(m, 1H), 1.4 – 1.5 (m, 3H), 1.1 - 1.2 (m, 10H), 0.72 (t, J = 6.5 Hz, 3H); 13C NMR (D2O, 
100 MHz) (chloride salt) δ 102.1, 93.1, 81.7, 80.7, 73.7, 73.31, 73.30, 72.8, 72.2, 71.3, 
69.9, 68.6, 68.4, 59.9, 53.1, 50.2, 48.7, 40.0, 31.2, 29.4, 29.0, 28.5, 28.2, 25.2, 22.2, 13.6; 
ESI/APCI calcd for C26H53N4O11 ([M+H]
+
) m/z; measured m/z. 
6-O-(3-Amino-3-deoxy-α-D-glucopyranosyl)-5-O-n-octylneamine (FG11). 
Please refer to the general procedure for the final synthesis of kanamycin B analogs. 
FG11 was obtained with 28% yield as a chloride salt. 
1
H NMR (D2O, 300 MHz) 
(chloride salt) δ 5.61 (d, J = 3.5 Hz, 1H, H-1´), 5.08 (d, J = 3.5 Hz, 1H, H-1´´), 3.0 - 4.2 
(m, 19H), 2.4 (m, 1H), 1.9 (m, 1H), 1.4 – 1.5 (m, 2H), 1.1 - 1.2 (m, 10H), 0.72 (t, J = 6.5 
Hz, 3H); 
13
C NMR (D2O, 100 MHz) (chloride salt) δ 101.3, 93.0, 82.0, 81.1, 73.7, 73.2, 
71.8, 71.1, 69.6, 68.7, 68.2, 64.9, 59.3, 54.9, 53.0, 49.0, 48.7, 39.9, 31.2, 29.4, 29.0, 28.6, 
27.9, 25.3, 22.2, 13.6; ESI/APCI calcd for C26H54N5O10 ([M+H]
+
) m/z 596.3865; 
measured m/z 596. 3865. 
4´-O-benzyl-5,6-O-benzylidene-1,3,2´,6´-Tetraazidoneamine (45a). To a 
solution of 14 (3.72 g, 7. 35 mmol) in CH2Cl2 (25 mL) was added TBAHS (0.75 g, 2.21 
mmol), followed by BnBr (0.97 mL, 8.09 mmol) and NaOH (25 mL, 1N aqueous 
solution). The mixture was refluxed at 60 
o
C overnight. When complete, CH2Cl2 was 
removed from the reaction mixture using a rotavapor and the obtained solution was 
extracted with EtOAc. The organic layer was then washed with 1 N aqueous HCl, water 
and brine, and then dried over solid Na2SO4. After removal of the solvent and purification 
with gradient column chromatography (hexane:EtOAc = 100:0 to 40:60), the product 45a 
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was obtained mixed with its regioisomer 45b in a 1/1 ratio (1.97 g, 3.31 mmol, 45%). 
1
H 
NMR (CDCl3, 300 MHz) (mixture of 45a and 45b) δ 7.3 – 7.4 (m, 10H), 5.56 (d, J = 3.4 
Hz, 1H), 5.52 (d, J = 3.8 Hz, 1H), 4.96 (d, J = 11.3 Hz, 1H), 4.85 (d, J = 11.7 Hz, 1H), 
4.70 (d, J = 11.7 Hz, 2H), 4.0 - 4.1 (m, 4H), 3.7 – 3.9 (m, 2H), 3.3 – 3.7 (m, 13H), 3.23 
(dd, J = 10.7, 3.8 Hz, 1H), 2.81 (d, J = 3.8 Hz, 1H), 2.50 (d, J = 3.8 Hz, 1H), 2.2 -2.4 (m, 
2H), 1.3 – 1.8 (m, 24H). 
3´-O-benzyl-5,6-O-benzylidene-1,3,2´,6´-Tetraazidoneamine (45b). Please 
refer to the synthesis of compound 45a. 
4´-O-benzyl-3´-O-n-octyl-1,3,2´,6´-Tetraazidoneamine (47a). To a solution of a 
mixture of 45a and 45b (1.22 g, 2.04 mmol) in anhydrous DMF (50 mL), n-octyl 
bromide (1.42 mL, 8.18 mmol), NaH (0.33 g, 8.18 mmol), and a catalytic amount of 
TBAI were added. The reaction was stirred at room temperature overnight. When 
complete, the reaction was quenched by addition of MeOH (5 mL) and was slowly 
poured into a mixture of ice and EtOAc. The aqueous layer was extracted with EtOAc. 
The combined organic layers were washed with 1 N aqueous HCl, water, saturated 
aqueous NaHCO3 and brine, and then dried over solid Na2SO4. After removal of the 
solvent, a brownish, oily crude product was obtained, to which 70 mL of a mixed solution 
of dioxane:H2O = 1:1 was added, followed by 50 mL glacial acetic acid. The resulting 
mixture was refluxed at 60 
o
C overnight. When complete, the reaction mixture was 
quenched with saturated aqueous NaHCO3 and extracted with EtOAc. The organic layer 
was washed with 1N aqueous HCl, water, saturated aqueous NaHCO3, brine, and dried 
over solid Na2SO4. After removal of the solvent followed by purification with a gradient 
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column chromatography (hexane:EtOAc = 100:0 to 40:60), a mixture of 47a and 47b was 
obtained in a 10/7 ratio (0.92 g, 1.46 mmol, 72%). 
1
H NMR (CDCl3, 300 MHz) (mixture 
of 47a and 47b) δ 7.3 – 7.4 (m, 10H), 5.12 (d, J = 3.7 Hz, 1H), 5.11 (d, J = 3.4 Hz, 1H), 
4.89 (d, J = 10.7 Hz, 1H), 4.87 (d, J = 10.3 Hz, 1H), 4.83 (d, J = 10.3 Hz, 1H), 4.63 (d, J 
= 1.0 Hz, 1H),  4.0 - 4.2 (m, 4H), 3.7 – 3.9 (m, 5H), 3.3 – 3.6 (m, 16H), 3.2 – 3.3 (m, 
4H), 2.8 (m, 1H), 2.3 (m, 2H), 1.4 – 1.7 (m, 6H), 1.2 (m, 20H), 0.87 (t, J = 7.2 Hz, 6H); 
13
C NMR (CDCl3, 100 MHz) δ 137.8 (2 carbons), 128.8 (4 carbons), 128.32, 128.27, 
128. 16 (2 carbons), 128.09 (2 carbons), 99.7 (2 carbons), 84.3 (2 carbons), 81.2 (2 
carbons), 80.9 (2 carbons), 79.1, 78.7 (2 carbons), 76.1, 75.8, 75.5, 74.2, 73.9, 71.7, 71.5, 
64.4 (2 carbons), 59.9 (2 carbons), 59.0 (2 carbons), 51.1 (2 carbons), 32.2 (2 carbons), 
32.0 (2 carbons), 30.6 (2 carbons), 29.7 (2 carbons), 29.4 (2 carbons), 26.3 (2 carbons), 
22.8 (2 carbons), 14.3 (2 carbons); ESI/APCI calcd for C27H40N12O6Na ([M+Na]
+
) m/z 
651.3086; measured m/z 651.3105. 
3´-O-benzyl-4´-O-n-octyl-1,3,2´,6´-Tetraazidoneamine (47b). Please refer to 
the synthesis of compound 47a. 
6-O-(2,3,4,6-Tetra-O-benzyl-α-D-glucopyranosyl)-4´-O-benzyl-3´-O-n-octyl-
1,3,2´,6´-tetraazidoneamine (48a). A solution of the mixture of 47a and 47b (0.20 g, 
0.32 mmol), 42a (0.24 g, 0.38 mmol), and activated powder 4 Å molecular sieve was 
stirred at room temperature for 2 h in 12 mL of a mixed anhydrous solution Et2O:CH2Cl2 
= 3:1. The mixture was cooled to -70 
o
C and N-iodosuccinimide (0.09 g, 0.38 mmol) was 
quickly added. After the temperature has warmed up to -40 
o
C, trifluoromethanesulfonic 
acid (0.05 mL) was added. The solution was stirred at low temperature till the complete 
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consumption of the glycosyl donor. The reaction mixture was quenched by addition of 
solid NaHCO3, Na2S2O3 and Na2SO4. After being stirred for 15 minutes, the reaction 
mixture was filtered through celite. The residue was washed thoroughly with EtOAc. 
After removal of the solvents, the crude product was purified with gradient column 
chromatography (Hexane:EtOAc = 100:0 to 50:50) to afford a mixture of 48a and 48b, 
obtained together with some inseparable impurities that prevented a full characterization. 
6-O-(2,3,4,6-Tetra-O-benzyl-α-D-glucopyranosyl)-3´-O-benzyl-4´-O-n-octyl-
1,3,2´,6´-tetraazidoneamine (48b). Please refer to the synthesis of 48a. 
6-O-(α-D-Glucopyranosyl)-3´-O-n-octylneamine (FG12). Please refer to the 
general procedure for the final synthesis of kanamycin B analogs. An inseparable mixture 
of FG12 and FG13 was obtained in 35% yield as chloride salts. The spectral information 
of only one of them (FG12 or FG13) is reported as follows: 
1
H NMR (D2O, 300 MHz) 
(chloride salt) δ 5.79 (d, J = 3.8 Hz, 1H), 4.95 (d, J = 3.1 Hz, 1H), 3.3 - 4.0 (m, 19H), 2.4 
(m, 1H), 1.7 - 1.9 (m, 1H), 1.4 – 1.5 (m, 2H), 1.1 - 1.2 (m, 10H), 0.71 (t, J = 6.9 Hz, 3H); 
13
C NMR (D2O, 100 MHz) (chloride salt) 101.8, 96.1, 84.0, 79.2, 77.6, 74.3, 73.0, 72.9 
(2 carbons), 71.7, 69.8, 69.3 (2 carbons), 60.6, 52.9, 49.9, 48.4, 40.1, 31.3, 29.5, 28.7, 
28.5, 25.3, 25.2, 22.2, 13.6; ESI/APCI calcd for C26H53N4O11 ([M+H]
+
) m/z 597.3705; 
measured m/z 597.3716. 
6-O-(α-D-Glucopyranosyl)-4´-O-n-octylneamine (FG13). Please refer to the 
synthesis of FG12. 
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1-Pentyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (50).
114 
Please refer to the 
general procedure for cycloaddition of 1,4-naphthoquinone, Method C. Compound 50 
was obtained in 40% yield.  
1-Hexyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (51). Please refer to the 
general procedure for cycloaddition of 1,4-naphthoquinone , Method C. Compound 51 
was obtained in 49% yield.
 1
H NMR (CDCl3, 300 MHz) δ 8.3 – 8.4 (m, 1H), 8.2 – 8.3 (m, 
1H), 7.8 – 7.9 (m, 2H), 4.85 (t, J = 7.2 Hz, 2H), 2.0 (m, 2H), 1.2 - 1.4 (m, 6H), 0.88 (t, J 
= 7.2 Hz, 3H); 
13
C NMR (CD3OD, 100 MHz) δ 177.1, 175.7, 145.8, 135.4, 134.5, 133.7 
133.5, 133.1, 128.1, 127.6, 50.9, 31.3, 30.2, 26.2, 22.6, 14.1; ESI/APCI calcd for 
C16H18N3O2
+
 ([M+H]
+
) m/z 284.1394; measured m/z 284.1390. 
1-Octyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (52).
114 
Please refer to the 
general procedure for cycloaddition of 1,4-naphthoquinone, Method C. Compound 52 
was obtained in 62% yield. 
1-Decyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (53).
114 
Please refer to the 
general procedure for cycloaddition of 1,4-naphthoquinone, Method C. Compound 50 
was obtained in 54% yield.  
1-Dodecyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (54).
114 
Please refer to 
the general procedure for cycloaddition of 1,4-naphthoquinone, Method C. Compound 50 
was obtained in 68% yield.  
2-Pentylamino-1,4-naphthoquinone (60).
57 
Please refer to the general procedure 
for cycloaddition of 1,4-naphthoquinone, Method B. Compound 60 was obtained in 29% 
yield (estimated from the integral ratio of 
1
H NMR). 
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2-Hexylamino-1,4-naphthoquinone (61). Please refer to the general procedure 
for cycloaddition of 1,4-naphthoquinone, Method B. Compound 61 was obtained in 18% 
yield (estimated from the integral ratio of 
1
H NMR). 
1
H NMR (CDCl3, 300 MHz) δ 8.0 – 
8.1 (m, 2H), 7.7 (m, 1H), 7.6 (m, 1H), 5.87 (br s, 1H), 5.72 (s, 1H), 3.16 (q, J = 7.2 Hz, 
2H), 1.7 (m, 2H), 1.2 -1.5 (m, 6H), 0.90 (t, J = 7.2 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) 
δ 183.1, 182.1, 148.2, 134.9, 133.9, 132.1, 130.7, 126.45, 126.39, 100.9, 42.8, 31.6, 28.4, 
26.9, 22.7, 14.2. ESI/APCI calcd for C16H20NO2
+
 ([M+H]
+
) m/z 258.1489; measured m/z 
258.1492. 
2-Octylamino-1,4-naphthoquinone (62).
120
 Please refer to the general procedure 
for cycloaddition of 1,4-naphthoquinone, Method B. Compound 62 was obtained in 11% 
yield (estimated from the integral ratio of 
1
H NMR). 
2-Decylamino-1,4-naphthoquinone (63). Please refer to the general procedure 
for cycloaddition of 1,4-naphthoquinone, Method B. Compound 63 was obtained in 3% 
yield (estimated from the integral ratio of 
1
H NMR). 
1
H NMR (CDCl3, 300 MHz) δ 8.0 – 
8.1 (m, 2H), 7.7 (m, 1H), 7.6 (m, 1H), 5.88 (br s, 1H), 5.73 (s, 1H), 3.16 (q, J = 7.2 Hz, 
2H), 1.7 (m, 2H), 1.2 -1.4 (m, 14H), 0.88 (t, J = 6.9 Hz, 3H); 
13
C NMR (CDCl3, 100 
MHz) δ 183.1, 182.2, 148.2, 135.0, 133.9, 132.1, 130.7, 126.5, 126.4, 100.9, 42.8, 32.1, 
29.9, 29.7 (2 carbons), 29.5, 28.5, 27.2, 22.9, 14.3 ESI/APCI calcd for C20H28NO2
+
 
([M+H]
+
) m/z 314.2115; measured m/z 314.2112. 
2-Dodecylamino-1,4-naphthoquinone (64).
123 
Please refer to the general 
procedure for cycloaddition of 1,4-naphthoquinone, Method B. Compound 64 was 
obtained in 4% yield (estimated from the integral ratio of 
1
H NMR). 
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3-Ethyl-1-pentyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-
ium chloride (50a). Please refer to the general procedure for N-3 alkylation. Compound 
50a was obtained in 80% yield. 
1
H NMR (CD3OD, 300 MHz) δ 8.36 (dd, J = 8.9, 2.7 Hz, 
2H), 8.04 (dd, J = 9.3, 2.4 Hz, 2H), 5.12 (q, J = 7.2 Hz, 2H), 5.06 (t, J = 7.2 Hz, 2H), 2.1 
– 2.2 (m, 2H), 1.74 (t, J = 7.2 Hz, 3H), 1.4 - 1.5 (m, 4H), 0.95 (t, J = 7.2 Hz, 3H); 13C 
NMR (CD3OD, 100 MHz) δ 171.2, 171.1, 134.4 (2 carbons), 134.31, 134.30, 131.2 (2 
carbons), 126.3 (2 carbons), 52.8, 48.6, 26.9, 26.5, 20.3, 11.4, 11.3; ESI/APCI calcd for 
C17H20N3O2
+
 ([M]
+
) m/z 298.1550; measured m/z 298.1543.  
3-Butyl-1-pentyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-
ium chloride (50b). Please refer to the general procedure for N-3 alkylation. Compound 
50b was obtained in 53% yield. 
1
H NMR (CD3OD, 300 MHz) δ 8.35 (dd, J = 9.3, 2.4 Hz, 
2H), 8.02 (dd, J = 9.3, 2.4 Hz, 2H), 5.07 (t, J = 7.2 Hz, 2H), 5.06 (t, J = 7.2 Hz, 2H), 2.1 
(m, 4H), 1.4 - 1.6 (m, 6H), 1.03 (t, J = 7.2 Hz, 3H), 0.95 (t, J = 7.2 Hz, 3H); 
13
C NMR 
(CD3OD, 100 MHz) δ 172.7 (2 carbons), 135.9 (4 carbons), 132.8 (2 carbons), 127.8 (2 
carbons), 54.3, 54.1, 30.6, 28.4, 28.1, 21.8, 19.3, 12.9, 12.4; ESI/APCI calcd for 
C19H24N3O2
+
 ([M]
+
) m/z 326.1863; measured m/z 326.1856.    
1,3-Dipentyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium 
chloride (50c). Please refer to the general procedure for N-3 alkylation. Compound 50c 
was obtained in 64% yield.
 1
H NMR (CD3OD, 400 MHz) δ 8.38 (dd, J = 9.0, 2.5 Hz, 
2H), 8.05 (dd, J = 9.0, 2.4 Hz, 2H), 5.08 (t, J = 7.2 Hz, 4 H), 2.1 (m, 4 H), 1.2 - 1.6 (m, 
8H), 0.98 (t, J = 7.1 Hz, 6H); 
13
C NMR (CDCl3, 100 MHz) δ 172.7 (2 carbons), 135.9 (4 
carbons), 132.8 (2 carbons), 127.9 (2 carbons), 54.3 (2 carbons), 28.4 (2 carbons), 28.1 
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(2carbons), 22.2 (2 carbons), 21.8 (2 carbons), 12.9 (2 carbons); ESI/APCI calcd for 
C20H26N3O2
+
 ([M]
+
) m/z 340.2020; measured m/z 340.2028.   
3-Octyl-1-pentyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-
ium chloride (50e). Please refer to the general procedure for N-3 alkylation. Compound 
50e was obtained in 74% yield.
 1
H NMR (CD3OD, 300 MHz) δ 8.37 (dd, J = 9.3, 2.4 Hz, 
2H), 8.04 (dd, J = 8.9, 2.4 Hz, 2H), 5.07 (t, J = 7.2 Hz, 4 H), 2.1 (m, 4 H), 1.3 - 1.5 (m, 
14H), 0.96 (t, J = 7.2 Hz, 3H), 0.89 (t, J = 6.9 Hz, 3H); 
13
C NMR (CD3OD, 100 MHz) δ 
172.7 (2 carbons), 136.0 (2 carbons), 135.9 (2 carbons), 132.8 (2 carbons), 127.9 (2 
carbons), 54.3 (2 carbons), 31.7, 29.0, 28.7 (2 carbons), 28.4, 28.1, 26.0, 22.5, 21.8, 13.2, 
12.9; ESI/APCI calcd for C23H32N3O2
+
 ([M]
+
) m/z 382.2489; measured m/z 382.2497.  
3-Decyl-1-pentyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-
ium chloride (50f). Please refer to the general procedure for N-3 alkylation. Compound 
50f was obtained in 58% yield.
 1
H NMR (CD3OD, 400 MHz) δ 8.4 (m, 2H), 8.1 (m, 2H), 
5.10 (t, J = 7.2 Hz, 4H), 2.1 (m, 4H), 1.2 – 1.6 (m, 18H), 0.8 – 1.0 (m, 6H); 13C NMR 
(CD3OD, 100 MHz) δ 172.7 (2 carbons), 136.0 (2 carbons), 135.9 (2 carbons), 132.7 (2 
carbons), 127.9 (2 carbons), 54.3 (2 carbons), 31.8, 29.4, 29.2 (2 carbons), 28.7 (2 
carbons), 28.5, 28.1, 26.0, 22.5, 21.8, 13.2, 12.9; ESI/APCI calcd for C25H36N3O2
+
 ([M]
+
) 
m/z 410.2802; measured m/z 410.2813.  
3-Ethyl-1-hexyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium 
chloride (51a). Please refer to the general procedure for N-3 alkylation. Compound 51a 
was obtained in 82% yield.
 1
H NMR (CD3OD, 300 MHz) δ 8.37 (dd, J = 8.9, 2.1 Hz, 
2H), 8.04 (dd, J = 8.9, 2.7 Hz, 2H), 5.13 (q, J = 7.2 Hz, 2H), 5.07 (t, J = 7.6 Hz, 2H), 2.1 
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(m, 2H), 1.73 (t, J = 7.2 Hz, 3H), 1.3 - 1.5 (m, 6H), 0.93 (t, J = 7.2 Hz, 3H); 
13
C NMR 
(CD3OD, 100 MHz) δ 172.73, 172.66, 135.9 (2 carbons), 135.8 (2 carbons), 132.8 (2 
carbons), 127.9 (2 carbons), 54.3, 50.2, 31.0, 28.7, 25.7, 22.2, 13.1, 13.0; ESI/APCI calcd 
for C18H22N3O2
+
 ([M]
+
) m/z 312.1707; measured m/z 312.1710. 
3-Butyl-1-hexyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium 
chloride (51b). Please refer to the general procedure for N-3 alkylation. Compound 51b 
was obtained in 95% yield.
 1
H NMR (CD3OD, 300 MHz) δ 8.34 (dd, J = 8.9, 2.4 Hz, 
2H), 8.01 (dd, J = 8.9, 2.8 Hz, 2H), 5.05 (t, J = 7.2 Hz, 2H), 5.04 (t, J = 7.2 Hz, 2H), 2.1 
(m, 4H), 1.2 - 1.6 (m, 8H), 1.02 (t, J = 7.2 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H); 
13
C NMR 
(CD3OD, 100 MHz) δ 172.8 (2 carbons), 135.9 (4 carbons), 132.8 (2 carbons), 127.8 (2 
carbons), 54.3, 54.1, 30.9, 30.6, 28.6, 25.7, 22.2, 19.3, 13.1, 12.4; ESI/APCI calcd for 
C20H26N3O2
+
 ([M]
+
) m/z 340.2020; measured m/z 340.2025. 
1-Hexyl-3-pentyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-
ium chloride (51c). Please refer to the general procedure for N-3 alkylation. Compound 
51c was obtained in 62% yield.
 1
H NMR (CD3OD, 400 MHz) δ 8.38 (dd, J = 9.1, 2.4 Hz, 
2H), 8.05 (dd, J = 9.1, 2.4 Hz, 2H), 5.08 (t, J = 7.3 Hz, 4H), 2.1 (m, 4H), 1.2 – 1.6 (m, 10 
H), 0.9 (m, 6H); 
13
C NMR (CD3OD, 100 MHz) δ 172.2 (2 carbons), 136.0 (4 carbons), 
132.8 (2 carbons), 127.9 (2 carbons), 54.3 (2 carbons), 31.0, 28.7, 28.4, 28.1, 25.7, 22.2, 
21.8, 13.1, 12.9; ESI/APCI calce for C21H28N3O2
+
 ([M]
+
) m/z 354.2176; measured m/z 
354.2178.  
1,3-Dihexyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium 
chloride (51d). Please refer to the general procedure for N-3 alkylation. Compound 51d 
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was obtained in 90% yield. 
1
H NMR (CD3OD, 300 MHz) δ 8.34 (dd, J = 8.9, 2.7 Hz, 
2H), 8.01 (dd, J = 9.3, 2.4 Hz, 2H), 5.05 (t, J = 7.2 Hz, 4H), 2.1 (m, 4H), 1.3 - 1.6 (m, 
12H), 0.92 (t, J = 7.2 Hz, 6H); 
13
C NMR (CD3OD, 100 MHz) δ 172.8 (2 carbons), 135.9 
(4 carbons), 132.8 (2 carbons), 127.8 (2 carbons), 54.3 (2 carbons), 30.9 (2 carbons), 28.6 
(2 carbons), 25.7 (2 carbons), 22.2 (2 carbons), 13.0 (2 carbons); ESI/APCI calcd for 
C22H30N3O2
+
 ([M]
+
) m/z 368.2333; measured m/z 368.2340. 
1-Hexyl-3-octyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium 
chloride (51e). Please refer to the general procedure for N-3 alkylation. Compound 51e 
was obtained in 88% yield.
 1
H NMR (CD3OD, 300 MHz) δ 8.35 (dd, J = 9.3, 2.4 Hz, 
2H), 8.02 (dd, J = 8.9, 2.4 Hz, 2H), 5.05 (t, J = 7.2 Hz, 4H), 2.1 (m, 4H), 1.3 - 1.6 (m, 
16H), 0.9 (m, 6H); 
13
C NMR (CD3OD, 75 MHz) δ 172.6 (2 carbons), 135.8 (4 carbons), 
132.7 (2 carbons), 127.7 (2 carbons), 54.2 (2 carbons), 31.6, 30.8, 28.8, 28.6, 28.53, 
28.52, 25.9, 25.6, 22.4, 22.1, 13.1, 13.0; ESI/APCI calcd for C24H34N3O2
+
 ([M]
+
) m/z 
396.2646; measured m/z 396.2650. 
3-Decyl-1-hexyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium 
chloride (51f). Please refer to the general procedure for N-3 alkylation. Compound 51f 
was obtained in 39% yield.
 1
H NMR (CD3OD, 300 MHz) δ 8.37 (dd, J = 8.9, 2.4 Hz, 
2H), 8.04 (dd, J = 8.9, 2.0 Hz, 2H), 5.08 (t, J = 7.2 Hz, 4H), 2.1 (m, 4H), 1.2 – 1.6 (m, 
20H), 0.9 (m, 6H); 
13
C NMR (CD3OD, 100 MHz) δ 172.7 (2 carbons), 136.1 (2 carbons), 
135.9 (2 carbons), 132.7 (2 carbons), 127.9 (2 carbons), 54.4 (2 carbons), 31.8, 31.0, 
29.4, 29.3, 29.2, 28.7 (3 carbons), 26.0, 25.7, 22.5, 22.3, 13.2, 13.1; ESI/APCI calcd for 
C26H38N3O2
+
 ([M
+
]) m/z 424.2959; measured m/z 424.2962. 
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3-Ethyl-1-octyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium 
chloride  (52a).
124 
Please refer to the general procedure for N-3 alkylation. Compound 
52a was obtained with 51% yield. 
3-Butyl-1-octyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium 
chloride (52b). Please refer to the general procedure for N-3 alkylation. Compound 52b 
was obtained in 99% yield.
 1
H NMR (CD3OD, 300 MHz) δ 8.35 (dd, J = 8.9, 2.8 Hz, 
2H), 8.02 (dd, J = 8.9, 2.4 Hz, 2H), 5.0 - 5.1 (m, 4H), 2.1 (m, 4H), 1.2 – 1.6 (m, 12H), 
1.03 (t, J = 7.2 Hz, 3H), 0.90 (t, J = 6.5 Hz, 3H); 
13
C NMR (CD3OD, 100 MHz) δ 172.8 
(2 carbons), 135. 9 (4 carbons), 132.8 (2 carbons), 127.8 (2 carbons), 54.3, 54.1, 31.7, 
30.6, 28.9, 28.71, 28.65, 26.0, 22.5, 19.3, 13.2, 12.5; ESI/APCI calcd for C22H30N3O2
+
 
([M]
+
) m/z 368.2333; measured m/z 368.2337. 
1,3-Dioctyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium 
chloride (52e). Please refer to the general procedure for N-3 alkylation. Compound 52e 
was obtained in 29% yield.
 1
H NMR (CD3OD, 300 MHz) δ 8.38 (dd, J = 8.9, 2.4 Hz, 
2H), 8.05 (dd, J = 8.9, 2.7 Hz, 2H), 5.10 (t, J = 7.2 Hz, 4H), 2.1 (m, 4H), 1.2 – 1.6 (m, 
H), 0.89 (t, J = 6.8 Hz, 6H);
 13
C NMR (CD3OD, 100 MHz) δ 172.6 (2 carbons), 136.1 (2 
carbons), 135.9 (2 carbons), 132.7 (2 carbons), 127.9 (2 carbons), 54.4 (2 carbons), 31.7 
(2 carbons), 30.0 (2 carbons), 28.9 (2 carbons), 28.7 (2 carbons), 26.0 (2 carbons), 22.5 (2 
carbons), 13.2 (2 carbons); ESI/APCI calcd for C26H38N3O2
+
 ([M]
+
) m/z 424.2959; 
measured m/z 424.2960. 
3-Decyl-1-octyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium 
chloride (52f). Please refer to the general procedure for N-3 alkylation. Compound 52f 
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was obtained in 81% yield. 
1
H NMR (CD3OD, 400 MHz) δ 8.40 (dd, J = 9.2, 2.4 Hz, 
2H), 8.06 (dd, J = 9.0, 2.5 Hz, 2H), 5.10 (t, J = 7.2 Hz, 4H), 2.1 (m, 4H), 1.2 – 1.6 (m, 
24H), 0.9 (m, 6H); 
13
C NMR (CD3OD, 100 MHz) δ 172.7 (2 carbons), 136.0 (2 carbons), 
135.9 (2 carbons), 132.8 (2 carbons), 127.9 (2 carbons), 54.4 (2 carbons), 31.8, 31.7, 
29.4, 29.3, 29.2, 28.9, 28.7 (4 carbons), 26.0 (2 carbons), 22.52, 22.49, 13.2 (2 carbons); 
ESI/APCI calcd for C22H30N3O2
+
 ([M]
+
) m/z 452.3280; measured m/z 452.3272.   
3-Ethyl-1-decyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium 
chloride (53a). Please refer to the general procedure for N-3 alkylation. Compound 53a 
was obtained in 99% yield. 
1
H NMR (CD3OD, 300 MHz) δ 8.32 (dd, J = 9.3, 2.4 Hz, 
2H), 8.00 (dd, J = 8.9, 2.4 Hz, 2H), 5.08 (q, J = 7.2 Hz, 2H), 5.01 (t, J = 7.6 Hz, 2H), 2.1 
(m, 2H), 1.72 (t, J = 7.2 Hz, 3H), 1.2 - 1.5 (m, 14H), 0.87 (t, J = 6.8 Hz, 3H); 
13
C NMR 
(CD3OD, 100 MHz) δ 172.9, 172.8, 135.9 (2 carbons), 132.8 (2 carbons), 127.8 (4 
carbons), 54.3, 50.2, 31.8, 29.4, 29.2 (2 carbons), 28.7, 28.6, 26.0, 22.5, 13.3, 12.9; 
ESI/APCI calcd for C18H22N3O2
+
 ([M]
+
) m/z 368.2333; measured m/z 368.2342. 
3-Butyl-1-decyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium 
chloride (53b). Please refer to the general procedure for N-3 alkylation. Compound 53b 
was obtained in 87% yield. 
1
H NMR (CD3OD, 300 MHz) δ 8.35 (dd, J = 8.9, 2.4 Hz, 
2H), 8.02 (dd, J = 9.3, 2.4 Hz, 2H), 5.07 (t, J = 7.2 Hz, 2H), 5.06 (t, J = 7.2 Hz, 2H), 2.1 
(m, 4H), 1.2 - 1.6 (m, 16H), 1.03 (t, J = 7.2 Hz, 3H), 0.88 (t, J = 6.9 Hz, 3H); 
13
C NMR 
(CD3OD, 100 MHz) δ 172.8 (2 carbons), 135.9 (4 carbons), 132.8 (2 carbons), 127.8 (2 
carbons), 54.3, 54.1, 31.8, 30.6, 29.4, 29.22, 29.20, 28.73, 28.65, 26.0, 22.5, 19.3, 13.2, 
12.4; ESI/APCI calcd for C24H34N3O2
+
 ([M]
+
) m/z 396.2646; measured m/z 396.2651. 
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1,3-Didecyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium 
chloride (53f). Please refer to the general procedure for N-3 alkylation. Compound 53f 
was obtained in 93% yield. 
1
H NMR (CD3OD, 300 MHz) δ 8.35 (dd, J = 9.3, 2.4 Hz, 
2H), 8.02 (dd, J = 9.3, 2.4 Hz, 2H), 5.06 (t, J = 7.2 Hz, 4H), 2.1 (m, 4H), 1.2 - 1.5 (m, 
28H), 0.88 (t, J = 7.2 Hz, 6H); 
13
C NMR (CD3OD, 100 MHz) δ 172.7 (2 carbons), 135.9 
(4 carbons), 132.8 (2 carbons), 127.9 (2 carbons), 54.3 (2 carbons), 31.8 (2 carbons), 29.4 
(2 carbons), 29.3 (2 carbons), 29.2 (2 carbons), 28.8 (2 carbons), 28.6 (2 carbons), 26.0 (2 
carbons), 22.5 (2 carbons), 13.3 (2 carbons); ESI/APCI calcd for C30H46N3O2
+
 ([M]
+
) m/z 
480.3585; measured m/z 480.3588. 
1-Dodecyl-3-ethyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-
ium chloride (54a). Please refer to the general procedure for N-3 alkylation. Compound 
54a was obtained in 99% yield. 
1
H NMR (CD3OD, 300 MHz) δ 8.35 (dd, J = 8.9, 2.4 Hz, 
2H), 8.02 (dd, J = 8.6, 2.4 Hz, 2H), 5.11 (q, J = 7.2 Hz, 2H), 5.04 (t, J = 7.2 Hz, 2H), 2.1 
(m, 2H), 1.73 (t, J = 7.2 Hz, 3H), 1.2 - 1.5 (m, 18H), 0.88 (t, J = 6.9 Hz, 3H);
 13
C NMR 
(CD3OD, 100 MHz) δ 172.8, 172.7, 135.9 (4 carbons), 132.8 (2 carbons), 127.8 (2 
carbons), 54.3, 50.2, 31.9, 29.5 (2 carbons), 29.4, 29.3, 29.2, 28.8, 28.7, 26.0, 22.5, 13.2, 
12.9; ESI/APCI calcd for C24H34N3O2
+
 ([M]
+
) m/z 396.2646; measured m/z 396.2639.  
3-Butyl-1-dodecyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-
ium chloride (54b). Please refer to the general procedure for N-3 alkylation. Compound 
54b was obtained in 93% yield.
 1
H NMR (CD3OD, 300 MHz) δ 8.33 (dd, J = 9.3, 2.4 Hz, 
2H), 8.00 (dd, J = 8.9, 2.4 Hz, 2H), 5.04 (t, J = 7.2 Hz, 2H), 5.03 (t, J = 7.2 Hz, 2H), 2.1 
(m, 4H), 1.2 - 1.6 (m, 20H), 1.01 (t, J = 7.2 Hz, 3H), 0.87 (t, J = 6.8 Hz, 3H); 
13
C NMR 
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(CD3OD, 100 MHz) δ 172.8 (2 carbons), 135.9 (2 carbons), 135.8 (2 carbons), 132.8 (2 
carbons), 127.8 (2 carbons), 54.3, 54.1, 31.9, 30.5, 29.5 (2 carbons), 29.4, 29.3, 29.2, 
28.7, 28.6, 26.0, 22.5, 19.3, 13.2, 12.5; ESI/APCI calcd for C26H38N3O2
+
 ([M]
+
) m/z 
424.2959; measured m/z 424.2958.  
1-Dodecyl-3-pentyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-
ium chloride (54c). Please refer to the general procedure for N-3 alkylation. Compound 
54c was obtained in 99% yield. 
1
H NMR (CD3OD, 300 MHz) δ 8.36 (dd, J = 9.3, 2.4 Hz, 
2H), 8.02 (dd, J = 8.9, 2.4 Hz, 2H), 5.07 (t, J = 7.2 Hz, 4 H), 2.1 (m, 4 H), 1.2 - 1.6 (m, 
22H), 0.95 (t, J = 6.8 Hz, 3H), 0.88 (t, J = 6.8 Hz, 3H); 
13
C NMR (CD3OD, 100 MHz) δ 
172.7 (2 carbons), 136.0 (2 carbons), 135.9 (2 carbons), 132.8 (2 carbons), 127.9 (2 
carbons), 54.3 (2 carbons), 31.9, 29.5 (2 carbons), 29.4, 29.3 (2 carbons), 28.74, 28.69, 
28.4, 28.1, 26.0, 22.5, 21.8, 13.2, 12.9; ESI/APCI calcd for C27H40N3O2
+
 ([M]
+
) m/z 
438.3128; measured m/z 438.3122.   
1-Dodecyl-3-hexyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-
ium chloride (54d). Please refer to the general procedure for N-3 alkylation. Compound 
54d was obtained in 88% yield.
 1
H NMR (CD3OD, 300 MHz) δ 8.35 (dd, J = 9.3, 2.4 Hz, 
2H), 8.02 (dd, J = 9.3, 2.4 Hz, 2H), 5.06 (t, J = 7.2 Hz, 4H), 2.1 (m, 4H), 1.2 - 1.6 (m, 
24H), 0.8 – 1.0 (m, 6H); 13C NMR (CD3OD, 100 MHz) δ 172.7 (2 carbons), 136.0 (2 
carbons), 135.9 (2 carbons), 132.8 (2 carbons), 127.9 (2 carbons), 54.4 (2 carbons), 31.9, 
31.0, 29.5 (2 carbons), 29.4, 29.3 (2 carbons), 28.8, 28.7 (2 carbons), 26.0, 25.7, 22.5, 
22.3, 13.2, 13.1; ESI/APCI Calcd for C28H42N3O2
+
 ([M]
+
) m/z 452.3273; measured m/z 
452.3273. 
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1-Dodecyl-3-octyl-4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-
ium chloride (54e). Please refer to the general procedure for N-3 alkylation. Compound 
54e was obtained in 52% yield.
 1
H NMR (CD3OD, 300 MHz) δ 8.37 (dd, J = 9.3, 2.4 Hz, 
2H), 8.05 (dd, J = 9.3, 2.4 Hz, 2H), 5.09 (t, J = 7.2 Hz, 4 H), 2.1 (m, 4 H), 1.2 - 1.5 (m, 
28H), 0.9 (m, 6H); 
13
C NMR (CD3OD, 100 MHz) δ 172.6 (2 carbons), 136.1 (2 carbons), 
135.9 (2 carbons), 132.7 (2 carbons), 127.9 (2 carbons), 54.4 (2 carbons), 31.9, 31.7, 29.5 
(2 carbons), 29.4, 29.3 (2 carbons), 29.0, 28.8 (4 carbons), 26.0 (2 carbons), 22.52, 22.48, 
13.2 (2 carbons); ESI/APCI calcd for C30H46N3O2
+
 ([M]
+
) m/z 480.3585; measured m/z 
480.3580.   
3-Decyl-1-dodecyl-4,9-dioxo-4,9-dihydro 1H-naphtho[2,3-d][1,2,3]triazol-3-
ium chloride (54f). Please refer to the general procedure for N-3 alkylation. Compound 
54f was obtained in 99% yield. 
1
H NMR (CD3OD, 300 MHz) δ 8.36 (dd, J = 8.9, 2.4 Hz, 
2H), 8.03 (dd, J = 8.9, 2.4 Hz, 2H), 5.07 (t, J = 7.2 Hz, 4 H), 2.1 – 2.2 (m, 4 H), 1.2 - 1.5 
(m, 32H), 0.88 (t, J = 6.9 Hz, 6H); 
13
C NMR (CD3OD, 100 MHz) δ 172.7 (2 carbons), 
136.0 (4 carbons), 132.8 (2 carbons), 127.9 (2 carbons), 54.4 (2 carbons), 31.9 (2 
carbons), 29.4 (2 carbons), 29.3 (4 carbons), 28.8 (2 carbons), 28.7 (2 carbons), 26.0 (2 
carbons), 22.5 (2 carbons), 13.2 (2 carbons); ESI/APCI calcd for C32H50N3O2
+
 ([M]
+
) m/z 
508.3898; measured m/z 508.3896. 
3-Methyl-1-hexyl-1H-naphtho[2,3-d][1,2,3]triazol-3-ium chloride (69). 
Compound 69 was synthesized according to the protocol described in reference 115. 
1
H 
NMR (CD3OD, 300 MHz) δ 8.3 – 8.4 (m, 2H), 8.0 (m, 2H), 5.04 (t, J = 7.2 Hz, 2H), 4.68 
(s, 3H), 2.1 (m, 2H), 1.3 - 1.6 (m, 6H), 0.93 (t, J = 7.2 Hz, 3H); 
13
C NMR (CD3OD, 100 
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MHz) δ 172.72, 172.65, 136.2, 136.0 (2 carbons), 135.6, 132.9, 132.7, 127.9, 127.8, 54.3, 
39.8, 31.0, 28.8, 25.7, 22.2, 13.1; ESI/APCI calcd for C17H20N3O2
+
 ([M]
+
) m/z 298.1550; 
measured m/z 298.1560. 
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Full BioMed Central Open Access license agreement 
(Identical to the 'Creative Commons Attribution License') 
License 
THE WORK (AS DEFINED BELOW) IS PROVIDED UNDER THE TERMS OF THIS 
BIOMED CENTRAL OPEN ACCESS LICENSE ("LICENSE"). THE WORK IS 
PROTECTED BY COPYRIGHT AND/OR OTHER APPLICABLE LAW. ANY USE 
OF THE WORK OTHER THAN AS AUTHORIZED UNDER THIS LICENSE IS 
PROHIBITED. 
BY EXERCISING ANY RIGHTS TO THE WORK PROVIDED HERE, YOU ACCEPT 
AND AGREE TO BE BOUND BY THE TERMS OF THIS LICENSE. THE 
LICENSOR GRANTS YOU THE RIGHTS CONTAINED HERE IN 
CONSIDERATION OF YOUR ACCEPTANCE OF SUCH TERMS AND 
CONDITIONS.  
1. Definitions 
a. "Collective Work" means a work, such as a periodical issue, anthology or 
encyclopedia, in which the Work in its entirety in unmodified form, along with a 
number of other contributions, constituting separate and independent works in 
themselves, are assembled into a collective whole. A work that constitutes a 
Collective Work will not be considered a Derivative Work (as defined below) for 
the purposes of this License. 
b. "Derivative Work" means a work based upon the Work or upon the Work and 
other pre-existing works, such as a translation, musical arrangement, 
dramatization, fictionalization, motion picture version, sound recording, art 
reproduction, abridgment, condensation, or any other form in which the Work 
may be recast, transformed, or adapted, except that a work that constitutes a 
Collective Work will not be considered a Derivative Work for the purpose of this 
License. For the avoidance of doubt, where the Work is a musical composition or 
sound recording, the synchronization of the Work in timed-relation with a moving 
image ("synching") will be considered a Derivative Work for the purpose of this 
License. 
c. "Licensor" means the individual or entity that offers the Work under the terms of 
this License. 
d. "Original Author" means the individual or entity who created the Work. 
e. "Work" means the copyrightable work of authorship offered under the terms of 
this License. 
f. "You" means an individual or entity exercising rights under this License who has 
not previously violated the terms of this License with respect to the Work, or who 
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has received express permission from the Licensor to exercise rights under this 
License despite a previous violation. 
2. Fair Use Rights 
Nothing in this license is intended to reduce, limit, or restrict any rights arising from fair 
use, first sale or other limitations on the exclusive rights of the copyright owner under 
copyright law or other applicable laws. 
3. License Grant 
Subject to the terms and conditions of this License, Licensor hereby grants You a 
worldwide, royalty-free, non-exclusive, perpetual (for the duration of the applicable 
copyright) license to exercise the rights in the Work as stated below: 
a. to reproduce the Work, to incorporate the Work into one or more Collective 
Works, and to reproduce the Work as incorporated in the Collective Works; 
b. to create and reproduce Derivative Works; 
c. to distribute copies or phonorecords of, display publicly, perform publicly, and 
perform publicly by means of a digital audio transmission the Work including as 
incorporated in Collective Works; 
d. to distribute copies or phonorecords of, display publicly, perform publicly, and 
perform publicly by means of a digital audio transmission Derivative Works; 
e. For the avoidance of doubt, where the Work is a musical composition:  
i. Performance Royalties Under Blanket Licenses. Licensor waives the 
exclusive right to collect, whether individually or via a performance rights 
society (e.g. ASCAP, BMI, SESAC), royalties for the public performance 
or public digital performance (e.g. webcast) of the Work. 
ii. Mechanical Rights and Statutory Royalties. Licensor waives the 
exclusive right to collect, whether individually or via a music rights 
agency or designated agent (e.g. Harry Fox Agency), royalties for any 
phonorecord You create from the Work ("cover version") and distribute, 
subject to the compulsory license created by 17 USC Section 115 of the 
US Copyright Act (or the equivalent in other jurisdictions). 
f. Webcasting Rights and Statutory Royalties. For the avoidance of doubt, where 
the Work is a sound recording, Licensor waives the exclusive right to collect, 
whether individually or via a performance-rights society (e.g. SoundExchange), 
royalties for the public digital performance (e.g. webcast) of the Work, subject to 
the compulsory license created by 17 USC Section 114 of the US Copyright Act 
(or the equivalent in other jurisdictions). 
The above rights may be exercised in all media and formats whether now known or 
hereafter devised. The above rights include the right to make such modifications as are 
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technically necessary to exercise the rights in other media and formats. All rights not 
expressly granted by Licensor are hereby reserved. 
4. Restrictions 
The license granted in Section 3 above is expressly made subject to and limited by the 
following restrictions: 
a. You may distribute, publicly display, publicly perform, or publicly digitally 
perform the Work only under the terms of this License, and You must include a 
copy of, or the Uniform Resource Identifier for, this License with every copy or 
phonorecord of the Work You distribute, publicly display, publicly perform, or 
publicly digitally perform. You may not offer or impose any terms on the Work 
that alter or restrict the terms of this License or the recipients' exercise of the 
rights granted hereunder. You may not sublicense the Work. You must keep intact 
all notices that refer to this License and to the disclaimer of warranties. You may 
not distribute, publicly display, publicly perform, or publicly digitally perform the 
Work with any technological measures that control access or use of the Work in a 
manner inconsistent with the terms of this License Agreement. The above applies 
to the Work as incorporated in a Collective Work, but this does not require the 
Collective Work apart from the Work itself to be made subject to the terms of this 
License. If You create a Collective Work, upon notice from any Licensor You 
must, to the extent practicable, remove from the Collective Work any reference to 
such Licensor or the Original Author, as requested. If You create a Derivative 
Work, upon notice from any Licensor You must, to the extent practicable, remove 
from the Derivative Work any reference to such Licensor or the Original Author, 
as requested. 
b. If you distribute, publicly display, publicly perform, or publicly digitally perform 
the Work or any Derivative Works or Collective Works, You must keep intact all 
copyright notices for the Work and give the Original Author credit reasonable to 
the medium or means You are utilizing by conveying the name (or pseudonym if 
applicable) of the Original Author if supplied; the title of the Work if supplied; to 
the extent reasonably practicable, the Uniform Resource Identifier, if any, that 
Licensor specifies to be associated with the Work, unless such URI does not refer 
to the copyright notice or licensing information for the Work; and in the case of a 
Derivative Work, a credit identifying the use of the Work in the Derivative Work 
(e.g., "French translation of the Work by Original Author," or "Screenplay based 
on original Work by Original Author"). Such credit may be implemented in any 
reasonable manner; provided, however, that in the case of a Derivative Work or 
Collective Work, at a minimum such credit will appear where any other 
comparable authorship credit appears and in a manner at least as prominent as 
such other comparable authorship credit. 
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5. Representations, Warranties and Disclaimer 
UNLESS OTHERWISE MUTUALLY AGREED TO BY THE PARTIES IN WRITING, 
LICENSOR OFFERS THE WORK AS-IS AND MAKES NO REPRESENTATIONS 
OR WARRANTIES OF ANY KIND CONCERNING THE WORK, EXPRESS, 
IMPLIED, STATUTORY OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, 
WARRANTIES OF TITLE, MERCHANTIBILITY, FITNESS FOR A PARTICULAR 
PURPOSE, NONINFRINGEMENT, OR THE ABSENCE OF LATENT OR OTHER 
DEFECTS, ACCURACY, OR THE PRESENCE OF ABSENCE OF ERRORS, 
WHETHER OR NOT DISCOVERABLE. SOME JURISDICTIONS DO NOT ALLOW 
THE EXCLUSION OF IMPLIED WARRANTIES, SO SUCH EXCLUSION MAY NOT 
APPLY TO YOU. 
6. Limitation on Liability 
EXCEPT TO THE EXTENT REQUIRED BY APPLICABLE LAW, IN NO EVENT 
WILL LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY FOR ANY 
SPECIAL, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR EXEMPLARY 
DAMAGES ARISING OUT OF THIS LICENSE OR THE USE OF THE WORK, 
EVEN IF LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH 
DAMAGES. 
7. Termination 
a. This License and the rights granted hereunder will terminate automatically upon 
any breach by You of the terms of this License. Individuals or entities who have 
received Derivative Works or Collective Works from You under this License, 
however, will not have their licenses terminated provided such individuals or 
entities remain in full compliance with those licenses. Sections 1, 2, 5, 6, 7, and 8 
will survive any termination of this License. 
b. Subject to the above terms and conditions, the license granted here is perpetual 
(for the duration of the applicable copyright in the Work). Notwithstanding the 
above, Licensor reserves the right to release the Work under different license 
terms or to stop distributing the Work at any time; provided, however that any 
such election will not serve to withdraw this License (or any other license that has 
been, or is required to be, granted under the terms of this License), and this 
License will continue in full force and effect unless terminated as stated above. 
8. Miscellaneous 
a. Each time You distribute or publicly digitally perform the Work or a Collective 
Work, the Licensor offers to the recipient a license to the Work on the same terms 
and conditions as the license granted to You under this License. 
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b. Each time You distribute or publicly digitally perform a Derivative Work, 
Licensor offers to the recipient a license to the original Work on the same terms 
and conditions as the license granted to You under this License. 
c. If any provision of this License is invalid or unenforceable under applicable law, 
it shall not affect the validity or enforceability of the remainder of the terms of 
this License, and without further action by the parties to this agreement, such 
provision shall be reformed to the minimum extent necessary to make such 
provision valid and enforceable. 
d. No term or provision of this License shall be deemed waived and no breach 
consented to unless such waiver or consent shall be in writing and signed by the 
party to be charged with such waiver or consent. 
e. This License constitutes the entire agreement between the parties with respect to 
the Work licensed here. There are no understandings, agreements or 
representations with respect to the Work not specified here. Licensor shall not be 
bound by any additional provisions that may appear in any communication from 
You. This License may not be modified without the mutual written agreement of 
the Licensor and You. 
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